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This review describes and summarizes the role of neuronal nitric oxide synthase (nNOS) on 
the central nervous system, particularly on brain regions such as the ventrolateral medulla (VLM) 
and the periaqueductal gray matter (PAG), and on blood vessels and the heart that are involved in 
the regulation and control of the cardiovascular system (CVS). Furthermore, we shall also review 
the functional aspects of nNOS during several physiological, pathophysiological, and clinical 
conditions such as exercise, pain, cerebral vascular accidents or stroke and hypertension. For 
example, during stroke, a cascade of molecular, neurochemical, and cellular changes occur that 
affect the nervous system as elicited by generation of free radicals and nitric oxide (NO) from 
vulnerable neurons, perioxide formation, superoxides, apoptosis, and the differential activation of 
three isoforms of nitric oxide synthases (NOSs), and can exert profound effects on the CVS. 
Neuronal NOS is one of the three isoforms of NOSs, the others being endothelial (eNOS) and 
inducible (iNOS) enzymes. Neuronal NOS is a critical homeostatic component of the CVS and 
plays an important role in regulation of different systems and disease process including 
nociception. The functional and physiological roles of NO and nNOS are described at the 
beginning of this review. We also elaborate the structure, gene, domain, and regulation of the 
nNOS protein. Both inhibitory and excitatory role of nNOS on the sympathetic autonomic nervous 
system (SANS) and parasympathetic autonomic nervous system (PANS) as mediated via different 
neurotransmitters/signal transduction processes will be explored, particularly its effects on the 
CVS. Because the VLM plays a crucial function in cardiovascular homeostatic mechanisms, the 
neuroanatomy and cardiovascular regulation of the VLM will be discussed in conjunction with the 
actions of nNOS. Thereafter, we shall discuss the up-to-date developments that are related to the 
interaction between nNOS and cardiovascular diseases such as hypertension and stroke. Finally, 
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we shall focus on the role of nNOS, particularly within the PAG in cardiovascular regulation and 
neurotransmission during different types of pain stimulus. Overall, this review focuses on our 
current understanding of the nNOS protein, and provides further insights on how nNOS modulates, 
regulates, and controls cardiovascular function during both physiological activity such as exercise, 
and pathophysiological conditions such as stroke and hypertension.  
 
1. Introduction 
Neuronal NOS is a very important member of a family of three enzymes known as nitric oxide 
synthases (NOSs) that catalyzes the production of NO from L-arginine, an α-amino acid that is 
used in the biosynthesis of urea, ornithine, agmantine, creatine, citrulline, and glutamate [1-4]. 
Neuronal NOS, also known as constitutive NOS (cNOS) or NOS1, is an isoenzyme because it is 
encoded by a different gene when compared to the other NOS isoforms. The gene that encodes 
nNOS is located on chromosome 12 in humans [2,5,6]. This review about nNOS is designed to 
elaborate the wide variety of roles, including its redox and antioxidant properties, played by nNOS 
within the cells, tissues, organs, peripheral nervous system, and the central nervous system, 
particularly the VLM and PAG that are directly and/or indirectly involved in the regulation, 
modulation, integration and control of the CVS in several physiological condition such as exercise 
and nociceptive pathways. Furthermore, we shall also summarize and review the functional aspects 
of nNOS during some pathophysiological and clinical conditions such as cerebral vascular 
accidents or stroke, hypertension and pain along with its antioxidant properties, the focus of this 
very important forum regarding nNOS. However, the functions, importance and clinical 
significance of nNOS will not be appreciated without a fundamental understanding of the role of 
NOSs and the actions of the final product, NO, on human and other mammalian systems, both in 
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physiological and pathophysiological states. Thus, a brief summary of a) NOSs and b) NO effects 
on the CVS, cardiovascular functions and other disease processes will be presented below. Overall, 
this review focuses on the physiological actions and regulatory functions of nNOS along with its 
pathological significance and clinical implications with particular emphasis on different 
components of the CVS and cardiovascular diseases such as stroke and hypertension. 
 
a) Isoforms of Nitric Oxide Synthases 
All three NOSs catalyze the following reaction that results in the final production of NO 
(Knowles and Moncada, 1994): 
2 L-arginine + 3 NADPH + 1 H+ + 4 O2    2 citrulline + 2 NO + 4 H2O + 3 NADP+ 
However, all three NOSs isoforms play a role in catalyzing other leak and side reactions, such as 
superoxide production at the expense of nicotinamide adenine dinucleotide phosphate or 
commonly known as NADP+ while the reduced form of NADP+ is abbreviated as NADPH [2]. 
Because all the three different family members of NOSs are encoded by separate genes, they are 
also known as isoforms or isoenzymes of NOS: two of them belong to the constitutive NOS 
(cNOS) and the third one is inducible NOS or iNOS. Experiments with cloning the NOSs enzymes 
have discovered that cNOS includes both brain constitutive (NOS1) or commonly known as 
neuronal constitutive (nNOS) and endothelial constitutive (NOS3) or endothelial NOS (eNOS), 
while the third isoenzyme that is cloned is named as the inducible (NOS2) gene or inducible NOS 
or iNOS [7,8]. In order to elaborate further, nNOS has been cloned from chromosome 12 located 
within nervous tissues and skeletal muscle type II, and its major function has been initially thought 
to be cellular communication [7,8]. On the other hand, iNOS was cloned from chromosome 17, 
located within the immune and the CVS, and the major function was elucidated as immune defense 
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against pathogens [7-9]. In addition, eNOS has been cloned from chromosome 7 within the 
endothelial cells with a very important function of causing vasodilation [7].  It should be noted 
that a drug called Ronopterin or VAS-203 or 4-amino-tetrahydrobiopterin (4-ABH4), an analogue 
of tetrahydrobiopterin (BH4), which is a cofactor of NOS, is a non-selective NOS antagonist that 
has been under research and development as a neuroprotective agent for the management of 
traumatic brain injury, such as stroke [1]. Finally, NOSs activity has also been demonstrated in 
several bacterial species that include some dangerous pathogens such as Bacillus anthracis and 
Staphylococcus aureus [10]. 
 
b) Nitric Oxide 
Although this review will focus on the effects of nNOS on the CVS and nociception, a brief 
description of the role of NO on cardiovascular activity is warranted, because of the fact that all 
three NOSs mediate their effects and actions via the final product which is NO. However, exactly 
how much NO is produced by each of the NOS isoenzyme in physiological state or in a disease 
condition is unknown, but under inflammatory conditions in the brain, a molecule of iNOS 
isoenzyme can generate 100-7000 times more NO than one molecule of the nNOS isoform [11]. 
Acting via the second messenger cyclic GMP (cGMP), NO is a very important neuronal mediator 
of intracellular signal transduction processes and has a wide range of physiological, 
pathophysiological, and pharmacological actions on numerous systems of humans and mammals, 
including the cardiovascular and the nervous systems [11-17]. The literature has numerous 
research publications, reviews, book chapters, and books on NO, including reviews on target 
validation of nNOS in physiological homeostasis as well as in several disease states. These 
diseases include but not limited to stroke and cardiovascular dysfunction; neurodegenerative 
disorders (e.g., Alzheimer’s disease, Parkinson’s-like symptoms); epilepsy, cerebellar 
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dysfunctions (e.g., essential tremor); autoimmune encephalomyelitis; brain, breast and lung 
cancers; systemic sclerosis; and skin lesions [18-23].   
The brainstem in the medulla oblongata contains several critical nuclei that control 
cardiovascular functions via the SANS which is strongly influenced by NO and oxygen free 
radicals. Long-term NOSs inhibition and less NO production have age-dependent consequences 
on radical signaling along with antioxidant or detoxificant properties [24]. Sleep deprivation has 
also been shown to result in endothelial dysfunction in addition to the development of hypertension 
via the NO signaling pathway, that can be reversed by L-arginine supplementation which can be 
easily administered orally [18]. There is ample evidence that the NO pathway has a strong 
correlation with cardiovascular diseases, cognitive impairment, and dementia [19]. A randomized, 
double-blind, and placebo-controlled trial has been proposed to evaluate the feasibility of sodium 
nitrate that will increase systemic levels of NO precursors in plasma as part of a treatment protocol 
for acute congestive heart failure [25]. In the same line, a short-term increase in dietary nitrate that 
will increase the availability of NO has been shown to reduce carotid atherosclerosis and ischemic 
cardiovascular disease in older women [26]. Even a randomized controlled trial of platelet 
inhibition by Prasugrel® (a thienopyridine derivative, a platelet inhibitor and an irreversible 
antagonist of P2Y12 ADP receptors) in patients with unstable angina pectoris has shown 
significant improvement in cardiovascular function mediated via an increase in endothelial NO 
bioavailability [27]. Finally, a recent review describes the interaction between reactive oxygen 
species (ROS) production and antioxidant activity associated with atherosclerosis, hypertension, 
heart failure and myocardial infarction [20]. Thus, it can be summarized that NO plays a major 
role not only in physiological homeostasis but also has a critical relationship with many diseases 
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associated with the cardiovascular and nervous systems such as stroke, hypertension and 
neurodegeneration. 
 
2. Gene Structure, Organization, Binding Sites and Receptors of Neuronal 
Nitric Oxide Synthase 
First discovered in 1990 after its neuronal isolation, nNOS has many applications in the 
development and homeostatic regulation of different mammalian systems [28]. From the onset of 
fetal development, nNOS plays a key role in the regulation of signaling and plasticity of neurons 
[28]. In order for the appropriate development to occur, nNOS is regulated physiologically 
according to the needs of the specific tissue and organ; it is regulated by phosphorylation and 
several phosphorylation sites for nNOS were already identified [29-31]. As a result, nNOS has 
been integrated in the evolutionary development of multiple vital enzymatic processes designed 
accordingly to specific neurons and cells [28]. Although the role of nNOS on the CVS has yet to 
be firmly established, numerous results from scientific medical research have reported the 
discovery of significant novel findings. These studies are specifically related to the biochemical 
properties, structural domain, and motif of nNOS, and the subsequent array of action of its final 
product, NO. This section will briefly summarize the role of the structure and domain of nNOS 
with particular emphasis on its effect on the CVS. 
a) Domain and Motif of Neuronal Nitric Oxide Synthase 
Although nNOS has been subdivided into multiple splicing variants like nNOSαa, 
nNOSαb, nNOSβ, and nNOSγ [32-34], we shall focus our review briefly on the general domain of 
the nNOS protein. The nNOS isoform exhibits a bidomain structure consisting of an N-terminal 
oxygenase domain and a C-terminal reductase domain [35]. The N-terminal domain bears binding 
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sites for heme, BH4 and L-arginine, whereas the C-terminal domain has binding sites 
corresponding to flavin-adenine dinucleotide (FAD), flavin-mononucleotide (FMN), and NADPH. 
The two nNOS domains are connected by a CaM-binding sequence, also known as CaM-
recognition site, and indicate the significance of CaM in affecting the catalytic activity by 
controlling the spatial orientation of these two regions as shown in Figure 1 [36,37]. Calmodulin 
is a sensor that resides within the intracellular space and regulates a multitude of different enzymes 
and ion channels, including the regulation or modulation of membrane transport proteins. 
Calmodulin transmits functional signals based on Ca2+ binding to CaM binding-motifs. It has been 
shown using cardiac magnetic resonance imaging (MRI) studies that nNOS plays a prominent role 
in modulating Ca2+ influx in the myocardial cells of the heart of mammals [38,39].  Furthermore, 
phosphorylation of nNOS at the SER847 sequence by CaM occurs in the hippocampal area of the 
rat brain following a transient focal ischemic attack [40]. Finally, it has been shown that increased 
intracranial pressure can induce a CaM-dependent protein kinase II (CaMPKII) mediated 
phosphorylation of nNOS at SER847 sequence in the rat hippocampus following an episode of 
subarachnoid hemorrhage.  Tetrahydrobiopterin (BH4) couples the reductive oxygen activation to 
L-arginine oxidation [41]. The BH4 binding site and the active-site pocket that consists of heme 
and L-arginine binding sites are vital for nNOS dimerization [42].  In addition, two-hybrid studies 
with oxygenase and reductase domains, respectively, in yeast demonstrate that the association of 
nNOS into active dimers involves interactions between the reductase domains and between the 
reductase and oxygenase regions [43].  Altogether, the structure of the nNOS isoform itself has a 
profound correlation with cardiovascular disorders including cerebral ischemia or stroke. Figure 1 




Figure 1: Bidomain structure of nNOS isoform and the splicing variants (nNOSβ and 
nNOSγ). The electrons donated by NADPH (nicotinamide adenine dinucleotide phosphate) to 
the reductase domain reach the oxygenase domain via two redox carriers, FAD (flavin-
adenine dinucleotide) and FMN (flavin mononucleotide). In the oxygenase domain, the 
electrons interact with heme and BH4 (tetrahydrobiopterin) to cause arginine oxidation to 
citrulline and NO (nitric oxide). 
 
 The location of nNOS on chromosome 12 holds tremendous clinical significance. For 
example, there is a significant difference between two species of rats (different only by one locus) 
in chromosome 12 and is associated with high contractility and lowered elasticity of resistance in 
the vasculature system during a rise in blood pressure, suggesting that within the two different 
congenital rat models, vascular remodeling and dysfunction can contribute to hypertension [5,44]. 
There is a paradoxical concept in the sense that both genetic subtypes are associated with the 
production of NO as well as regulation of vascular hypertension and are encoded within the same 
gene. Therefore, in order to further our knowledge about nNOS and its subsequent formation of 
NO would require future research on hypertension at the genetic and molecular levels.  
b) Binding Sites 
The binding sites located on the nNOS protein molecule are particularly examined for their 
individual as well as their combined abilities in order to further understand the physiology of the 
CVS as well as to elucidate the factors which contribute to cardiovascular and other diseases. For 
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example, with regards to the designation of the BH4 binding site, it has been discovered that a 
pharmacological treatment with BH4 has shown to reverse pulmonary hypertension in a rat 
hypoxia model [45]. Similarly, the nNOS binding site for L-arginine is regarded with a greater 
interest. As people get older, peripheral arteries have a dwindling ability to dilate, due to 
endothelial dysfunction, particularly when such sequence of events within the vascular system 
furthers the risk of cardiovascular disease (CVD) with increasing age. L-arginine contributes to 
numerous physiological processes including nitrogen detoxification, immune-competency, growth 
hormone (GH) secretion, and insulin secretion and a considerable amount of attention has been 
placed on the ability of this amino acid to affect the overall vascular endothelial functions [46]. 
Reactive oxygen species play a large role in the pathogenesis of vascular diseases, and 
therefore, a careful consideration of nNOS’s relationship with NADPH cannot be underestimated. 
Scientists and researchers have been focused on the NADPH oxidase (NOX) family with reference 
to a large variety of ischemic and ROS-mediated vascular diseases. The NOX family (including 
seven isoforms of the NADPH oxidase catalytic unit) is quite unique as they also generate the 
ROS. The relevant enzymatic isoforms which are associated with vasculopathies are the NOX1, 
NOX2, and NOX4 of the NOX family [47]. Genetic mutations which are associated with a loss of 
NOX1 functionality have been shown to lower the occurrence of ROS-induced retinopathy in 
mouse models [47]. A reduction of ROS activity can lower the incidence of vascular injury. An 
actively working nNOS molecule moves charged electrons from NADPH, through the FAD and 
FMN (carboxy-terminal domain) to the heme (amino-terminal oxygenase domain; Figure 1). An 
essential cofactor BH4 binds the molecule oxygen and L-Arginine to the oxygenase domain.  
Ultimately at the amino-terminal oxygenase domain, these electrons are used to reduce and 
activate oxygen (O2) as well as to oxidize L-arginine to L-citrulline and NO [48] (Figure 1). Finally, 
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by using electrons from NADPH to ultimately produce NO, the nNOS isoform plays the role of 
reducing the production of ROS and at the same time eliciting vasodilation and smooth muscle 
relaxation. 
c) Advanced Structure of Neuronal Nitric Oxide Synthase 
 Neuronal NOS protein consists of 1434 amino acids and a molecular weight of 161 kDa 
[49]. Multiple mRNA transcripts of nNOS can be generated via alternate promoter usage, 
alternative splicing, and cassette insertions/deletions. In addition, some transcripts are directly 
translated into the nNOS protein isoform with modified structure and/or functions [50]. The full-
length transcript (without excisional mRNA codon removal) translation initiates in exon 2 results 
in a 161 kDa protein designated as nNOSα while deletion of exon 2 in stem cells forms two shorter 
splice variants, nNOSβ (136 kDa) and nNOSγ (125kDa) [33,34].  Figure 2 illustrates the different 
splice variants of the nNOS family.  
 
Figure 2. Difference between nNOS α and nNOS β splice variants. Serine, Threonine, 
Arginine), Tetrahydrobiopterin, Calmodulin, Flavin mononucleotide, Flavin adenine 
dinucleotide, and Nicotinamide adenine dinucleotide phosphate are common structural 
components present in all the splice variants of nNOS (neuronal nitric oxide synthase). The 
arrows indicate the direction of phosphorylation at the respective sites on NOS (nitric oxide 
synthase) activity.  
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Tetrahydrobiopterin (BH4) couples the reductive oxygen activation to L-arginine oxidation 
[41]. The BH4 binding site and the active-site pocket that consists of heme and L-arginine binding 
sites are vital for nNOS dimerization [42].  As mentioned above, the association of nNOS into 
active dimers involves interactions between the reductase domains and between the reductase and 
oxygenase regions [43]. The CaM sequence stimulates nNOS catalytic activity and electron 
transfer into its flavin and heme centers [51]. Neuronal NOS contains PDZ (PSD-95, discs-large 
and zona occludens-1) domains which consist of a consensus sequence of 90 amino acids that 
mediate protein-protein interactions via localization of nNOS to appropriate sites in the neuron 
[52-54]. As mentioned previously, there are three specific and distinct forms of NOS: iNOS, eNOS 
and nNOS, and all of these isoenzymes are expressed in cardiac myocytes with some variations. 
For example, the activity of iNOS has been detected in a variety of cell types, including endocardial 
and endothelial cells, vascular smooth muscle cells, fibroblasts, and neonatal and adult cardiac 
myocytes from several species [55]. 
d) Receptors Associated with Neuronal Nitric Oxide Synthase 
Neuronal NOS is located at the postsynaptic membrane and attached to the N-terminal 
PSD/Discs-large/ZO-1 homologous (PDZ)-binding domain, which is subsequently attached to the 
N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor family or NMDAR [28]. The 
NMDAR is driven by an influx of Ca2+ from the synaptic cleft, which will also propel the 
production of NO for signal potentiation [28]. Calcium is the primary regulator of nNOS 
transcription and activity; Ca2+ binding to CaM results in an electron transfer from the C-terminal 
(flavin domain) to the N-terminal (heme domain) by the displacement of an autoinhibitory insert, 
resulting in the biosynthesis of NO [56]. Neuronal NOS is transported to the Ca2+ handling 
proteins, such as the NMDAR-Ca2+ channel associations [57]. The crucial relationship between 
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nNOS and NMDAR has been described through observations regarding homocysteine, which 
activates NMDAR in the central nervous system [58,59]. Homocysteine disrupts the production 
and activity of the NO molecule. Because of the fact that NO functions to decrease vascular smooth 
muscle cell propagation, its suppression by homocysteine could promote myointimal hyperplasia 
and narrowing of a blood vessel. Therefore, high homocysteine levels are considered a risk factor 
for cardiovascular diseases. This relationship demonstrates the vital role that nNOS plays with the 
NMDAR and the Ca2+ channels; further elaborating its essential role in the homeostasis of multiple 
organ systems, including the CVS, and their interactions with each other. Figure 3 is a schematic 
illustration of such nNOS and NMDAR interactions. 
 
Figure 3.  Negative feedback loop for nNOS control of Ca2+ entry through NMDA 
receptor. The entry of Ca2+ into the cell is coupled to nNOS (neuronal nitric oxide synthase) 
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through the PDZ domain, PSD-95. As the level of Ca2+ in the cell increases, nNOS-derived NO 
(nitric oxide) acts on glutamate receptors (Both NMDA (N-methyl-D-aspartate) and AMPA) in 
order to inhibit further entry of Ca2+ by S-nitrosylation reaction. 
 
e) Regulation of Neuronal Nitric Oxide Synthase 
There are a number of molecular regulators of nNOS that are active within the human body. 
For example, the heat shock protein 90 (HSP90) stimulates nNOS activity by increasing its binding 
to Ca2+/CaM [60]. HSP90 is upregulated with increased nNOS expression. On the other hand, 
caveolae 1 (Cav-1) and caveolae 3 (Cav-3) proteins are downregulated by an increase in nNOS 
expression [61]. Caveolae are invaginations of the plasma membrane which are rich in cholesterol 
and sphingolipids. There are three isoforms of caveolins or the structural proteins of caveolae. For 
example, Cav-1 functions to generate caveolae in non-muscle cell types and provides for 
membrane localization of Cav-2. Then, Cav-3 is needed to form caveolae in skeletal, cardiac, and 
smooth muscle cells [62]. Studies using a model of genetically-engineered mice which lack 
caveolin genes have given researchers the ability to properly understand the importance of each 
distinct NOS isoforms which may contribute to the pathophysiology of many human diseases. It 
has been shown that Cav-1 KO (gene knockout) mice develop a severe type of cardiomyopathy, 
which shortens their lifespans significantly [62]. However, Cav-3 is actually predominant in 
cardiac myocytes and in the heart of a Cav-3 KO mouse; levels of cyclic AMP (cAMP) and the β-
adrenergic second messenger signaling mechanism in association with ATP production are 
inhibited or decreased [62]. The Cav-1 KO mice also have an overactive production of all NOSs 
due to the previously mentioned inverse relationship between Cav-1 and nNOS activity. A change 
in NOSs activity in Cav-1 KO mice can be linked to the development of cardiopulmonary 
pathologies due to its critical roles on cardiovascular homeostasis, vascular tone, vascular 
remodeling, platelet aggregation, and angiogenesis [62]. Another regulator of nNOS is HSP70, 
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which has been shown to be generated within the rostral ventrolateral medulla (RVLM) neurons 
resulting in an overexpression of the nNOS protein [63,64]. This may explain the neuroprotection 
during toxic septic shock as a result of endotoxins in the blood. In addition, the mechanisms 
underlying neuroprotection involve an enhancement of protein kinase G (PKG) signaling pathway 
and inhibition of the nNOS/peroxynitrite pathway that prevents cardiovascular depression [63,64]. 
In addition, evidence suggests that the autoinhibitory domain physiologically modulates nNOS 
activity wherein nNOS functions as structural element that is displaced upon calmodulin binding, 
resulting in loss of inhibition of NO synthesis [65]. Oxidative stress can induce phosphorylation 
of neuronal NOS in cardiomyocytes through AMP-activated protein kinase (AMPK) [66]. Finally, 
a novel protein that is named Protein Inhibitor of Neuronal Nitric-oxide Synthase (PIN) has been 
shown to bind to a 17-Amino Acid Residue Fragment of the nNOS and it provides further insights 
into the nNOS inhibition mechanism by PIN [67]. 
As mentioned above, the generation of NO is linked to the NMDAR, which under normal 
physiological process will limit NO production to small amounts. Unfortunately, pathological 
processes such as hypertension (HTN) and cerebrovascular accidents (CVA) may damage or alter 
this delicate process resulting in an abundance of NO generation [28]. Nitric oxide neurotoxicity 
can thus be exacerbated by oxygen free radicals and other ROS that arise from post injury status 
resulting in further degradation of proteinaceous material. Although caustic, this inflammatory 
phenomenon does not occur in neurons that possess nNOS possibly due to proximity interactions 
with phosphofructokinase (PFK1), which would protect the neurons through regulation of 
glycolysis. It has been shown that nNOS expression increases with CVA, and also causes changes 
in the homeostatic regulation of heart rate, blood pressure, myocardial contractility, and the 
autonomic nervous system (ANS); both physiologically and during times of 
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stress/activity/exercise [68-71]. In summary, we have briefly described the structure, domain, 
location, motif, receptors involved, and regulation of nNOS, and its relationship with certain 
cardiovascular activities. The following section 3 will further elaborate on specific roles of nNOS 
on the CVS in both physiological and pathological states. 
 
3. Role of Neuronal Nitric Oxide Synthase on Cardiovascular Functions in 
Physiological and Pathological States 
Cardiovascular diseases are the leading cause of morbidity and mortality in this entire world, 
with myocardial infarction and stroke being the first and the third killer diseases, respectively, in 
the United States of America [72]. The time and money spent, the research performed on 
myocardial cells and the heart itself, and the plethora of studies done on regulatory mechanisms of 
cardiovascular function in both physiological and pathological situations as described in the 
medical literature are extraordinarily enormous. Among all the numerous receptors, various 
neurotransmitters, neural pathways and signaling mechanisms that are involved with the CVS, NO 
is a very important determinant for maintaining basal vascular tone; preventing platelet activation 
and aggregating; limiting the adhesion of white blood cells to the endothelial wall of the 
vasculature; controlling myocardial contractility; and mediating, modulating and integrating the 
regulation of the CVS [15,16,22,73].  In addition, NO has been identified as a key player in the 
pathogenesis of common cardiovascular diseases that include hypotensive shock, development of 
essential hypertension, and formation of atherosclerosis [74,75].  On October 12, 1998, the Nobel 
Prize Assembly awarded the Nobel Prize in Medicine to three scientists, Robert Furchgott, Louis 
Ignarro, and Ferid Murad, for their discoveries that NO is a key signaling molecule in the CVS. In 
the following paragraphs, we shall discuss the past and current literature regarding the role of 
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nNOS on many aspects of the CVS such as cardiac myocytes, the heart, the vasculature, the 
different regions of the brain, several cardiovascular reflexes, and on cardiovascular regulatory 
mechanisms, i.e., the SANS and the PANS. 
a) Cardiac Myocytes and Cardiac Functions: Role of Neuronal Nitric Oxide Synthase 
An area of concern, as it pertains to the viability of the mammalian organism, is the CVS 
and the effects of nNOS on its regulation. Neuronal NOS, throughout the years of research, has 
been expanded from an identifying term used for just one protein to a family of variants consisting 
of nNOSαa, nNOSαb, nNOSβ and nNOSγ that are present on all muscle cell types including 
cardiac myocytes [68-71]. A study has identified that nNOS as well as Ca2+-CaM-dependent 
CaMPKII and NOX2 are important mediators in mechanical and chemical transduction processes 
that occur during cardiac contraction, and may provide new therapeutic approaches for treating 
stress-induced Ca2+ dysregulation, arrhythmias, and cardiomyopathy [76,77]. Cardiac muscle cells 
are regulated by several mechanisms: intrinsically via the automaticity of the sinoatrial node, 
atrioventricular node, and the purkinje fibers via L and T types of Ca2+ channels and extrinsically 
via the SANS and the PANS, the two divisions of the autonomic nervous system or ANS.  
Neuronal NOS is present inside the sarcoplasmic reticulum (SR) of cardiac myocytes (Figure 4) 
and allows more Ca2+ to exit the SR and resulting in positive ionotropic and dromotropic effects 
[78-80]. Neuronal NOS also increases phospholamban protein levels which inhibit SERCA and 
ultimately result in a decreased SR Ca2+ concentration [79]. Inhibition of SERCA and a 
simultaneous augmentation of phospholamban levels have negative ionotropic and dromotropic 
effects on cardiac myocytes. An increase or a decrease in nNOS activity in the regulation of 
intrinsic activity of cardiac muscle cells defines the positive or negative ionotropic and 
dromotropic effect, respectively.  
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Neuronal NOS is involved in the control of cardiac muscle contraction. Inhibition of nNOS 
activity via gene disruption or by acute pharmacological blockade enhances basal cardiac 
contractility at physiological temperatures and over a wide range of heart rates [81,82]. An increase 
in left ventricular (LV) ejection fraction has been observed in nNOS-/- mice compared with wild 
type nNOS littermates, without any significant change in heart rate or blood pressure between the 
two strains [83]. In isolated LV myocytes, nNOS inhibition results in a Ca2+-mediated positive 
ionotropism [81,83]. 
 
Figure 4: Effect of nNOS on calcium handling. The process of excitation-contraction coupling 
begins with the entry of calcium (Ca2+) into the cell via the calcium current that triggers the 
further release of Ca2+ from sarcoplasmic reticulum. This stimulation of intracellular Ca2+ 
initiates and propagates contraction. Neuronal nitric oxide synthase (nNOS) have significant 
effects on myocyte contraction under basal conditions and via Beta-1 adrenergic receptor 
stimulation. 
 
In addition, the nNOS-derived NO increases the activity of Na+-K+-ATPase that indirectly affects 
the Ca2+ fluxes via an action on intracellular sodium (Na+) levels, resulting in a change in the 
activity of the Na+-Ca2+ exchanger [84]. Neuronal NOS-induced production of NO inhibits the L-
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type Ca2+ current via the NO-cGMP pathway as a result of attenuating guanylate cyclase-derived 
increases in peak Ca2+ current, and PKG phosphorylation elicits a decrease in the basal levels [85]. 
It is possible that this mechanism also involves a change in the redox state of the Ca2+ channel. In 
addition, nNOS-derived NO exerts a negative feedback effect on Ca2+ handling as the increase in 
intracellular Ca2+-mediated stimulation of nNOS synthesis and subsequent generation of NO 
further inhibits Ca2+ fluxes. Finally, nNOS plays a role in the regulation of proteins involved in 
Ca2+ handling via the Ca2+ channels that are linked to the ryanodine receptors [86]. Thus, in the 
myocardium, nNOS activity is regulated by beat-to-beat variations in intracellular Ca2+ levels [83].  
 The roles of oxidants and reactive oxygen species (ROS), including nNOS, on Ca2+ and 
Na+ movements in healthy and diseased cardiac myocytes and other pathological conditions such 
as cardiac ischemia-reperfusion injury have been well established. A review in the literature 
describes the protective effects of nNOS after ischemia-reperfusion injury, with particular 
emphasis on the subcellular localization of nNOS at the molecular level and the subsequent targets 
of its action [87]. Ischemic postconditioning can provide protection of the heart following an 
ischemia-reperfusion injury to the heart mediated via nNOS located within the SR and 
mitochondria [88]. The L-type Ca2+ channel activity and myofilament Ca2+ sensitivity in cardiac 
myocytes can be modulated by the nNOS protein in hypertensive rats [89]. The deleterious effects 
of chronic ethanol consumption on the levels of Brain Natriuretic Peptide (BNP) and subsequent 
expression of the nNOS isoform within cardiac myocytes contribute to worsening of cardiac 
remodeling and may lead to progression of cardiomyopathy [90].  Neuronal NOS decreases 
myocardial contractility via the inhibition of the L-type Ca2+ current amplitude and the intrinsic 
Ca2+ transients, and both mitochondria and xanthine oxidoreductase have been identified as 
potential targets for nNOS in cardiac disease animal models [82]. 
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On the other hand, both the basal tone and positive inotropic responses mediated via β-1 
adrenergic receptor stimulation with low and high concentrations of isoproterenol are not mediated 
by nNOS in the LV myocytes [82]. However, one study reports a reduction in the inotropic 
response in nNOS-/- myocytes at room temperature [86]. It has been shown that the anti-
hypertrophic and antioxidant effects of β3-adrenergic stimulation in myocytes require differential 
expression of nNOS phosphorylation [91]. The literature agrees that nNOS is solely responsible 
for the NO-mediated autocrine regulation of myocardial contraction and relaxation [92]. In 
addition, studies using nNOS inhibitors support the involvement of NO in cardiac arrhythmias 
where direct stimulation of the vagus nerve in rabbits promotes NO release via the nNOS protein 
within the ventricles of the heart [93,94]. NO release due to nNOS stimulation within the LV due 
to vagal nerve stimulation has antiarrhythmic effects in the heart [94]. Finally, an atrial-specific 
upregulation of micro RNA-31 in human atrial fibrillation is a key mechanism that results in the 
loss of atrial dystrophin and nNOS proteins which may lead to the electrical phenotype induced 
by atrial fibrillation [95]. Overall, we summarize that nNOS has very important and serious 
implications on cardiac myocytes and cardiac functions in both physiological and pathological 
situations such as cardiac remodeling and heart failure, and is evolving into a potential therapeutic 
tool for pharmacological interventions in many disease states. 
b) Vasculature and Neuronal Nitric Oxide Synthase 
Although the eNOS protein is the predominant regulator of arterial blood pressure via 
vasodilatation, nNOS is also present on endothelial cells and significantly contributes to the 
modulation of vascular perfusion [96,97].  Interestingly, other studies report that nNOS is 
expressed in endothelial cells and participates in the endothelial-dependent control of vascular 
relaxation [98,99].  Smooth muscle is found throughout the mammalian vasculature imbedded in 
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the tunica media of most arterial circulatory system and some of the venous system. Homeostatic 
mechanisms at the autocrine and paracrine level result in an immediate vasodilatory effect during 
times of increased demand or increased blood pressure as a direct consequence of NO that 
increases the diameter of the vascular lumen, and thereby, decreasing vascular resistance by a 4-
fold. Since 2009, emerging data propose that eNOS and nNOS have their separate distinctive roles 
in the physiologic local regulation of human microvascular tone in vivo that triggered further 
studies regarding the differential contribution of nNOS and eNOS in vascular regulation as 
observed in several human diseases [100-104]. In addition, a study using RT-PCR confirms the 
endothelial expression of both nNOS and eNOS, and that the differential distribution of NOS 
isoforms in brain blood vessels might explain their separate modes of activation [105]. In a disease 
state like essential hypertension, it has been shown that impaired mental stress-induced nNOS-
mediated vasodilatation directly correlates with the increased sympathetic activity in hypertensive 
patients [101]. Thus, nNOS has serious consequences on the human circulatory system that is 
regulated by the brain. 
On the other hand, nNOS plays a critical role in the transcription of regulatory systems within 
the endothelial cells during ocular hemo-vasculogenesis, vasculogenesis, and overall angiogenesis 
[102]. Neuronal NOS also regulates the dynamics of renal blood flow via acetylcholine-induced 
vasodilation or by norepinephrine/angiotensin II elicited renal vasoconstriction [106]. 
Furthermore, a study demonstrates that the nNOS isoform is a critical regulator of renal 
hemodynamics in the newborn piglet kidney [103]. It is worthy to note that the protein expression 
of nNOS is maximal within the trigeminal vascular system and other brain structures related to 
pain-related circulatory changes in rats [107]. Moreover, the nNOS-derived NO-cyclic GMP 
pathway has the potential to be an important target for the treatment of renal circulatory 
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dysfunction, including chronic kidney failure and uremia [108]. The heat-shock protein HSP-90 
has been identified as a signaling mediator of nNOS-dependent vasodilatory response in 
mesenteric arteries, observed in portal hypertensive states [109]. Indeed, local nNOS-derived 
release of NO is a critical regulator of basal blood flow in the human coronary vascular bed; 
thereby suggesting that nNOS has its own distinctive role in the physiological regulation of human 
coronary vascular tone in vivo [110]. It has been previously shown that nNOS predominantly 
increases production of NO during decreased periarteriolar oxygen tension, resulting in 
vasodilation as seen during a state of low blood pressure [111]. Another study indicates that nNOS 
inhibition by pharmacological interventions can improve, at least in part, the hippocampal 
dysfunction after an attack of brain ischemia [105].  Overall, we summarize the role of nNOS 
protein on the vasculature during both physiological state and pathological situations that can lead 
to further development of strategies in the treatment protocol of vascular disorders such as 
ischemia.  
c) Sympathetic Autonomic Nervous System and Parasympathetic Autonomic Nervous 
System: Role of Neuronal Nitric Oxide Synthase  
Both the SANS and the PANS have significant roles in the regulation, integration, and 
modulation of cardiovascular functions during physiological homeostasis as well as throughout 
pathophysiological situations like myocardial infarction or stroke. The ANS of the heart is divided 
into intrinsic and extrinsic divisions; additionally, the extrinsic ANS of the heart contains nerves 
that regulate communication between the central nervous system (CNS) and the heart while the 
intrinsic division of the cardiac ANS contains autonomic nerves that are present within the 
pericardial cavity and within the heart [112]. Many processes such as cellular properties of 
myocytes, the hemodynamics, blood pressure, and heart rate are regulated by the ANS [112]. 
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Parasympathetic interaction in the CVS stimulates acetylcholine release which can be counteracted 
with sympathetic epinephrine release; additionally, cholinergic stimulus plays an important 
predominant role in cardiovascular protection against heart failure and ventricular arrhythmias 
[113,114]. For example, electrophysiological modulation of the cardiac cycle by the ANS is 
crucial, especially in circumstances such as atrial fibrillation where activation of parasympathetic 
or antiarrhythmic cycles and inhibition of sympathetic or arrhythmic periods are crucial for 
keeping a patient alive [113,114]. Activation of the PANS within the atria is antiarrhythmic while 
SANS activation is proarrhythmic in both the atria and ventricles. The origin of both the SANS 
and PANS is within the brainstem or the CNS and most of the studies done on nNOS that regulates 
cardiovascular function and activity via SANS and PANS are performed on brain regions that 
regulate/modulate their effects. Thus, we shall further summarize the role of nNOS on the ANS in 
the following paragraphs (see below). However, it is important to mention that parasympathetic 
stimulation is partly regulated by NO which stimulates the release of acetylcholine and controls 
functions like vascular resistance and myocardial contraction. In vivo inhibition of nNOS in guinea 
pigs has shown a reduced vagal stimulation leading to tachycardia; this indicates that NO controls 
antiarrhythmic processes through the vagus nerve (cranial nerve X) originating from the medulla 
[115,116]. In addition, research also supports the theory that acetylcholine release facilitates the 
production of NO through nNOS activation via a NO-cGMP pathway within the pacemaker cells 
present in the sinoatrial and atrioventricular nodes [117]. The role of nNOS on both SANS and 
PANS will be further described in an integrated way in the following sub-sections. 
d) Brain Regions Associated with Cardiovascular Regulation and Functions: Role of 
Neuronal Nitric Oxide Synthase 
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The CNS (the brain and the spinal cord) regulates the CVS in two separate processes: First, a 
feed-forward regulation, commonly known as the "central command" and second, the feedback or 
reflex regulation such as the baroreflex; both of these general mechanisms integrate in order to 
contribute to overall cardiovascular homeostasis. Among numerous receptors, neurotransmitters, 
neuromodulators, and neural mechanisms/pathways that are associated with cardiovascular 
functions, the NO signaling cascade and nNOS protein are crucial in contributing to their 
regulatory processes. Both NO and nNOS are present in almost all the neurons within the 
cardiovascular regulatory centers in the brain, including the nucleus tractus solitarii (NTS), the 
nucleus ambiguous, the hypothalamus, the dorsal motor nucleus of the vagus, the VLM, and also 
in vagal afferents [118-120]. After reviewing the literature for the last several decades, we find the 
VLM as a critical region within the medulla oblongata of the brainstem that is involved in 
numerous receptor- and neurotransmitter-mediated regulatory processes, integration of afferent 
and efferent signals from and to the heart and the entire body, and in a vast cascade of mechanisms 
involving the coordination of the CVS in both healthy and diseased individuals [121-127]. Both 
anatomically and functionally, the VLM has been separated into the caudal (CVLM) or depressor 
region and the RVLM or pressor area; this mapping of the VLM was derived from exploratory 
experiments using several animal species [128-131]. In addition to the VLM, the hypothalamus, 
particularly the posterior part, plays a critical role in coordinating or fine-tuning all cardiovascular 
functions, and that both NO molecules and nNOS protein contribute to the overall mechanisms of 
cardiovascular activity [132-135]. Finally, the NTS region of the brain along with its nNOS 
associated neuronal network that is located within the dorsal area of the medulla has been 
implicated in regulating the CVS, and plays the most important role in baroreflex mechanism [136-
144]. There are significant interactions and reciprocal connections among the three regions of the 
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brain: the VLM, the NTS and the hypothalamus. For example, the VLM plays a part in the 
integration of vasopressive responses projecting from the hypothalamus [145]. Therefore, the 
following paragraphs in this section will separately review the interactions of nNOS with 
neurotransmission and cardiovascular regulation within the VLM, the NTS, and the hypothalamus. 
The RVLM and the CVLM are now established as the two most critical regions in our brains 
for the maintenance of blood pressure and vasomotor tone, baroreceptor and the exercise pressor 
reflexes, cardiopulmonary reflex mechanisms, and the overall sympathetic tone [121-127].  
Afferent impulses originating from many rostral areas of the brain are also relayed onto these 
RVLM and/or CVLM neurons where they are integrated and the final responses are either an 
increase or a decrease in their neuronal activity in order to maintain cardiovascular homeostasis; 
however, the RVLM being the predominant regulatory center of both the SANS and PANS. Nitric 
oxide, derived from all NOSs, plays a crucial role in regulating sympathetic nerve activity but the 
nNOS isoform has a predominant sympathoinhibitory effect under physiological conditions by its 
action on different regions of the brain, including the hypothalamus, the NTS, and both the RVLM 
and CVLM [146,147]. On the other hand, nNOS within the RVLM and CVLM is 
sympathoinhibitory in pathological conditions like congestive cardiac failure, chronic renal failure, 
hypertension, and diabetes. Both Redox-sensitive inhibition of nNOS-mediated nNOS uncoupling 
is associated with an overproduction of ROS within the RVLM, and may result in the sympathetic 
overactivity-induced hypertension that is observed in Metabolic Syndrome [148]. Direct activation 
of the endocannabinoid G protein-coupled receptor causes hypotension in conscious rats and is 
mediated via the nNOS isoform [149]. An enhanced orexinergic input along with a potentiated 
nNOS signaling may modulate the activity of RVLM neurons and result in hypertension in 
spontaneously hypertensive rats [150]. 
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To add to the plethora of the effects of nNOS, a study demonstrates the existence and increased 
activation of the nNOS protein within the neurons of the RVLM during static skeletal muscle 
contraction- or exercise-induced increases in blood pressure and heart rate [151]. All the three 
eNOS-, nNOS-, and iNOS-cGMP signal transduction mechanisms within the RVLM and CVLM 
are associated with the regulation of cardiovascular function via alterations in central sympathetic 
outflow, and that intracerebroventricular (i.c.v.) injection or local administration of specific nNOS 
antagonists increases the baseline mean arterial blood pressure or MAP [152-154]. In contrast, 
i.c.v. administration of an NO donor lowers both MAP and heart rate (HR) associated with an 
increase in the expression of nNOS mRNA within the RVLM [155].  Our laboratory has shown 
that microdialysis of the drug, 1-(2-trifluoromethylphenyl)-imidazole (TRIM; Tocris Bioscience, 
Ellisville, MO, USA), a selective nNOS antagonist, at a dose of 1 µM bilaterally into the RVLM 
for 60 minutes does not alter baseline cardiovascular variables, however, a dose of 100 µM indeed 
lowers both MAP and HR [13,21]. It should be mentioned that although 1 µM TRIM was 
microdialyzed into the RVLM, in vitro recovery studies show that the microdialysis membrane 
only allows about 20±2% of the TRIM to actually diffuse throughout the RVLM area. Thus, the 
actual amount of TRIM that has been delivered through the mircodialysis probes inserted into the 
RVLM in our study was in a concentration that is unable to alter baseline blood pressure but was 
able to modulate the exercise pressor reflex (see below). This is in contrast to other studies where 
specific nNOS blockers at higher concentrations delivered by either microinjection techniques or 
by means of i.c.v. administration were able to change the baseline MAP and HR [156]. In addition 
to alterations of the iNOS isoform and the eNOS protein within the RVLM and CVLM, our 
laboratory has shown significant changes in the expression of the nNOS enzyme in experiments 
with a one-sided temporary ischemia using rat models of stroke [21,157]. Expression of the nNOS 
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protein within the ipsilateral RVLM following a transient left-sided focal ischemia or stroke is 
significantly reduced when compared with the contralateral RVLM, but not in the RVLM of intact 
rats. In contrast, the expression of the nNOS isoenzyme within the ipsilateral CVLM following an 
acute episode of stroke is markedly or significantly potentiated relative to that in the contralateral 
CVLM, suggesting that unilateral ischemic stroke differentially affects ipsilateral nNOS protein 
abundance within the RVLM and the CVLM [158]. 
In addition to its increased or decreased expression, there is evidence that the nNOS protein 
has significant interactions with glutamate, an excitatory amino acid, and gamma aminobutyric 
acid or GABA, the inhibitory amino acid, in the regulation of the CVS. Our laboratory has 
demonstrated that alteration in the nNOS activity within the RVLM and CVLM can play 
differential roles in static muscle contractions-induced increases in cardiovascular responses via 
an interaction with glutamatergic and GABAergic neurotransmission [159]. Within the RVLM, an 
nNOS-mediated surge of the release of GABA has been shown to act as a major 
sympathoinhibitory amino acid neurotransmitter along with decreased superoxide activity [160]. 
An enhanced expression of nNOS can also increase GABA but attenuate sympathoexcitatory 
angiotensin II signaling along with glutamate neurotransmission [146]. Swimming exercise has 
been shown to cause vasodilation mediated by an enhanced NO release, possibly via nNOS and 
associated with a reduction of glutamate levels within the RVLM in awake rats [161]. We have 
shown that NO within the RVLM and CVLM differentially modifies cardiovascular responses in 
addition to altered glutamate and GABA concentrations/release during skeletal muscle contraction 
or static exercise following stroke [118]. Excitatory glutamatergic and inhibitory GABAergic 
neurotransmission within the RVLM and CVLM are altered in stroke rats, and that such 
modulation of neurotransmitter release changes the expression of NOSs and affects cardiovascular 
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functions [158,162]. Blockade of nNOS within the RVLM increases glutamate release and 
decreases GABA levels, and the result is enhanced pressor and tachycardic responses to exercise, 
whereas nNOS antagonism within the CVLM causes attenuation of blood pressure and HR 
increases during exercise mediated via a reduction in neuronal glutamate release and an increase 
in GABA levels within the CVLM [163].  Thus, we have summarized the interactions among 
nNOS, cardiovascular functions, and glutamate/GABA interactions within the medulla oblongata. 
Figure 5 depicts the role of nNOS and neurotransmission in the overall control of cardiac function. 
In addition to the VLM, studies are also performed to elucidate the role of nNOS within the 
NTS and the hypothalamus on cardiovascular activity. Inhibition of nNOS within the NTS 
attenuates the ionotropic activity of the heart in response to an administration of glutamate agonists 
[142]. Administration of nNOS antagonists within the NTS alters the NO-induced GABA and 
glutamate release and modulates cardiovascular activity [141]. Because of the fact that the NTS 
plays the most important role in the baroreflex mechanism, further discussion of the role of NO on 
baroreflex is described in the following paragraph. On the other hand, the hypothalamus has been 
implicated in the fine tuning of the overall CVS activities, including the human circadian rhythms 
and diurnal variations in blood pressure as controlled by the central clock located within the 
suprachiasmatic nucleus (SCN) of the hypothalamus. Understanding how the hypothalamus is 
involved in the regulation of the circadian rhythm of blood pressure is critical in the treatment of 
circadian blood pressure dysfunction and essential hypertension [125]. A recent review 
summarizes the role of nNOS as well as other neurotransmitters that describes how hypothalamic 
inflammation elicited by NO over-production can disrupt crucial signaling cascades in order to 
disturb the central control of blood pressure, and suggests future development of interventional 
strategies related to the hypothalamic regulation of cardiovascular function, including the 
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inflammatory-sympathetic mechanisms involved in hypertension [126]. Particularly, the 
paraventricular nucleus (PVN) of the hypothalamus is a very important central fine-tuning site for 
integration of sympathetic outflow and cardiovascular function, including a role in the exaggerated 
sympathetic outflow commonly observed in heart failure [64,132]. Within the PVN, the production 
of NO generated by the nNOS protein plays a critical role in the inhibitory regulation of 
sympathetic outflow, and that studies in the rat model of experimental heart failure, the nNOS-NO 
mediated control mechanisms within the PVN is depressed. In summary, we can state that indeed 
both NO and nNOS within the hypothalamus as well as within the NTS play significant roles in 
the overall regulation of the CVS.  
e) Cardiovascular Reflexes:  Role of Neuronal Nitric Oxide Synthase 
These following paragraphs will describe the role of nNOS on cardiovascular reflexes such 
as the baroreflex and the exercise pressor reflex: two important cardiovascular reflexes that occur 
in our daily lives. It has been recognized by now that nNOS plays a critical function in autonomic 
neurotransmission [83,157]. The baroreflex or the baroreceptor reflex is a very important 
homeostatic mechanism involved in the maintenance of blood pressure and HR at a normal 
physiological range. It is a negative feedback control mechanism where an elevation of blood 
pressure reflexively lowers HR and vice versa, or a decrease in blood pressure deactivates the 
baroreflex activation, causing HR to increase: the result is to restore blood pressure at the normal 
range. However, in situations like exercise, fear, anger, and sexual intercourse the baroreflex is in 
a reset or shutdown mode where one will observe profound increases in both blood pressure and 
HR. The baroreceptors, located on the arch of the aorta and at the bifurcation of the common 
carotid arteries, monitor the fluctuations in arterial blood pressure, and play an important role in 
dealing with situations like postural or orthostatic hypotension, the tendency for blood pressure to 
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decrease on standing from a supine position [145]. Congruent with current concepts, the medulla 
oblongata, particularly the NTS and the VLM, controls baroreceptor reflexes and subsequent 
vascular responses are mediated by alterations in the central sympathetic vasomotor outflow 
[144,145]. Thus, sympathetic vascular control as well as baroreceptor activity can be specifically 
attributed to neurons present in the RVLM and the NTS. The glossopharyngeal nerve, the Hering 
nerve, and the vagus nerve are involved in the control of baroreflex activity. The NO-nNOS system 
also plays an important role in coordinating this baroreflex mechanism. For example, it has been 
shown that selective inhibition of nNOS reduces vagally-mediated bradycardia [115,116]. In 
addition, systemic administration of nNOS inhibitors affects baroreflex activity via modulating 
peripheral autonomic transmission, postsynaptic responsiveness of target tissues to autonomic 
stimuli, and autonomic circuits within the CNS [83]. Chronic interference of the nNOS protein 
dimerization that is responsible for the production of NO within the PVN of the hypothalamus 
potentiates the elevations in blood pressure via modulating the sympathoexcitation associated with 
renovascular hypertension [164]. The next paragraph will summarize the other roles of nNOS in 





Figure 5.  The role of nNOS in autonomic control of cardiac function. (Top) In the central 
nervous system, NO (nitric oxide) derived from nNOS (neuronal nitric oxide synthase) and eNOS 
(endothelial nitric oxide synthase) causes inhibition of sympathetic outflow and stimulation of 
vagal outflow via augmentation of GABA (γ-amino butyric acid)-mediated neuronal activity and 
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inhibition of glumatergic neurons, respectively. (Bottom) In the periphery, NO derived from 
nNOS decreases the release of NE (norepinephrine) and possibly glutamate and stimulates the 
release of ACh (acetylcholine) and GABA that results in the inhibition of cardiac responses to 
sympathetic nerve stimulation and the facilitation of negative chronotropic action of vagal 
stimulation, respectively. 
 
There have been many studies on the role of NO and nNOS on baroreflex functions. Delivery 
of an adenovirus-nNOS gene into the RVLM has been shown to improve baroreflex function in 
rats with congestive heart failure [89,116,165,166]. Another study suggests that nNOS-derived 
NO facilitates sympathetic baroreflex transmission within the RVLM via a soluble guanylate 
cyclase-dependent and a superoxide-independent mechanism [167]. The ventral portion of the 
medial prefrontal cortex (vMPFC) is known to be involved in the modulation of the PANS arm of 
the baroreflex mechanism. A study suggests that glutamatergic neurotransmission within the 
vMPFC exerts a tonic facilitatory influence on the PANS component of the baroreflex and 
mediated via an nNOS-NMDAR interaction within the vMPFC [168]. Studies using nNOS knock-
out mice show that the absence of nNOS activity results in an elevated baseline blood pressure and 
affects the transmission of baroreflex signals [169]. An nNOS-cGMP pathway at the CVLM area 
also augments the baroreceptor induced reflex bradycardia while that NO, specifically the nNOS 
isoform, mediates sympathetic cardiac-cardiovascular responses including the baroreflex through 
its action within the RVLM [170,171]. In addition, protein kinase A-dependent nNOS activation 
is required for the enhancement of baroreflex activity in response to the action of adrenomedullin, 
a peptide hormone with several functions including vasodilation, regulation of hormone secretion, 
promotion of angiogenesis, and antimicrobial activity (https://www.ncbi.nlm.nih.gov/gene/133; 
Gene ID: 133, updated on 27 January 2018), within the NTS of rats [172]. Moreover, an attenuated 
expression of nNOS protein within the NTS inhibits sympathetically mediated baroreflex 
responses in the rat [173]. Even an upregulation of the nNOS protein is seen after activation of 
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central angiotensin II type 2 receptors that improves arterial baroreflex sensitivity in rats with heart 
failure, and that nNOS attenuates the cardiac sympathetic drive and improves baroreflex control 
of HR in ovine heart failure [57,174]. Thus, we should recognize the profound influence of nNOS 
and NO on the baroreflex mechanism in both physiological and pathophysiological states. 
The “exercise pressor reflex” was first coined by Dr. Jere H. Mitchell from the Moss Heart 
Center of the University of Texas Southwestern Medical Center in Dallas, TX, USA. Dr. Mitchell 
has been a mentor of the first author of this review paper. The exercise pressor reflex can be 
described as follows: Static exercise or isometric skeletal muscle contraction as observed during 
push-ups, rowing a boat, weight-lifting and exercising with the dumbbells, sends impulses via the 
group III and IV muscle afferents within the spinal cord to activate neurons in the medulla 
oblongata, particularly within the RVLM and the CVLM where they are integrated, and the final 
results are increases in MAP, HR, myocardial contractility, cardiac output, and sympathetic nerve 
activity [175-179]. This paragraph will discuss how nNOS within the RVLM and the CVLM 
modulates cardiovascular responses along with alterations in glutamate and GABA 
neurotransmission during the exercise pressor reflex. The presence of nNOS within the RVLM 
plays a key regulatory role in the maintenance of cardiovascular functions in response to changes 
in mean arterial pressure, pathophysiological conditions and skeletal muscle excitation or 
relaxation. Our laboratory has several  publications on the modulation of cardiovascular functions, 
alterations of the nNOS, eNOS and iNOS protein expressions, and changes in adrenergic, 
serotonergic, dopaminergic, glutamatergic and GABAergic neurotransmission in response to static 
exercise following pharmacological interventions using NO precursor, nNOS, iNOS and eNOS 
antagonists, Angiotensin II type-2 (AngII type 2) receptor antagonism or blockade of Ang II  type-
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1 receptors, and opioid receptor agonists/antagonists, as well as NMDA and AMPA receptor 
blockers, among others that date back to 1994 [180-187]. 
First, expression of nNOS protein within the neurons of the RVLM increases during the 
exercise pressor reflex [151]. Our data show that nNOS antagonism within the RVLM for greater 
than two hours results in exaggerated cardiovascular responses (pressor and tachycardic) 
associated with a decrease in nNOS protein expression within the RVLM [13,159]. Conversely, a 
two-hour antagonism with a specific nNOS inhibitor administered into the CVLM decreases nNOS 
expression and attenuates the pressor and tachycardic responses during skeletal muscle 
contraction.  In addition, inhibition of nNOS within the RVLM and CVLM appears to be 
differentially controlling cardiovascular responses during the exercise pressor reflex via alterations 
in glutamate and GABA concentrations [13,159]. Pharmacological antagonism of the nNOS 
protein within the RVLM increases glutamate release and decreases the concentrations of GABA; 
the result being an augmented or enhanced exercise pressor reflex, while blockade of the nNOS 
isoform by administration of its antagonist into the CVLM results in attenuating the exercise 
pressor reflex via reducing neuronal glutamate release and increasing GABA levels [12]. Overall, 
it appears that the cardiovascular regulatory and reflex mechanisms orchestrated by the VLM in 
physiological homeostasis are under the influence of an excitatory and an inhibitory coordination 
among the nNOS protein and its synthesized NO molecules and glutamatergic and GABAergic 
neurotransmission [12,157]. The role of nNOS on cardiovascular functions in pathophysiological 
states such as stroke or hypertension will be described in the following sections. 
4. Hypertension and Neuronal Nitric Oxide Synthase 
Hypertension is one of the leading causes of morbidity and mortality in humans. There are 
approximately 8 million deaths and 92 million disabilities worldwide every year that are linked to 
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high blood pressure. Hypertension increases the risk of serious cardiovascular diseases, such as 
coronary heart disease (CHD), congestive heart failure (CHF), ischemic and hemorrhagic stroke, 
kidney failure, and peripheral arterial/vascular disease. It is also known as the “silent killer” and 
the chances of debilitating cardiovascular disease associated with hypertension increases if the 
patient has certain risk-factors such as obesity, diabetes mellitus, and high cholesterol. With proper 
antihypertensive pharmacological and non-drug therapy, the risks of further cardiovascular and 
renal complications can be lessened, even though a large segment of hypertensive patients are 
either untreated or improperly managed. While several classes of antihypertensive drugs are 
available for the management of hypertension, including resistant hypertension, the exact plethora 
of factors, etiology, pathogenesis, and pathophysiological mechanisms of almost 90% of the 
hypertensive population (primary or idiopathic hypertension) is still unclear. However, many 
mechanisms such as the renin-angiotensin-aldosterone system, SANS, PANS, intravascular 
volume, and vascular problems associated with hypertension are well-established. 
While there have been more than 60,000 scientific publications on NO in the last 20+ years, 
one interesting definitive conclusion is that people with clinically diagnosed atherosclerosis, 
diabetes, or hypertension often show impaired NO signaling pathways. Numerous studies also 
implicate that a high salt dietary intake decreases the production of NO in patients suffering from 
essential hypertension that affects approximately 90% of the patients. The following paragraphs 
will discuss past and recent findings about the relationship between hypertension and nNOS-
induced NO production. Whether or not the nNOS protein-induced production of NO will be able 
to prevent or treat any disease in humans is still unknown. However, investigations on nNOS using 
humans are still ongoing. For example, the importance of nNOS-hydrogen peroxide (H2O2) 
signaling pathways in the human internal mammary artery and saphenous vein, the commonly 
38 
 
used vessels used in coronary artery bypass grafting is still under active research, where the H2O2 
produced in the coronary circulation has been shown to increase the susceptibility to accelerated 
atherosclerosis with subsequent dysfunction of the saphenous vein [188].  Another recent study 
implies that the nNOS-derived NO plays a very critical role in the physiological regulation of basal 
systemic vascular resistance and blood pressure in healthy humans [189,190]. Neuronal NOS 
attenuates the cardiac oxidase enzymes that are shown to ameliorate the sources of oxidative stress-
related pathology in diseased hearts [191,192]. Finally, cardiac eNOS protein expression is 
decreased but the abundance of the nNOS protein along with its activity is significantly increased 
in hypertension [193]. In the same line, the nNOS isoenzyme abundance is the result of an interplay 
between angiotensin II (Ang II) type 1 receptor (AT1R) and Ang II type 2 receptor mediated via 
NADPH oxidase and ROS-dependent nNOS activity in cardiac myocytes. Therefore, the up-
stream and/or downstream expression of nNOS in the heart in a case of hypertensive patient may 
provide further understanding of the underlying mechanisms in hypertensive cardiomyopathy 
[192]. 
Vasodilators, angiotensin converting enzymes (ACE) inhibitors, or angiotensin II receptor 
blockers (ARBs) are commonly used as therapies for the treatment of hypertension and the effect 
of the drugs is producing vasodilation. In section 3, we have extensively discussed the role of 
nNOS on blood vessels and therefore we shall not repeat those findings. In addition, another 
therapy of hypertension is using drugs like clonidine that act on the CNS. The effects of NO and 
nNOS on the CNS and sympathoinhibition are also described in section 3. Thus, this paragraph 
will evaluate other past and current findings of the role of nNOS in hypertension. The fact that 
nNOS produces H2O2 and superoxide which are key mediators in non-neuronal cells signaling, 
suggests the importance of further exploring the role of nNOS in vascular homeostasis and 
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cardiovascular diseases such as hypertension and atherosclerosis [194].  In addition, nNOS 
contributes to the control of blood pressure in compensation for a decrease in eNOS expression 
[195]. Indeed, nNOS-derived H2O2 has been implicated in endothelial dysfunction in hypertension 
[196]. Finally, the importance of exercise in our daily lives is fully recognized not only for a 
healthy life but also for the prevention and therapy of diseases like hypertension, stroke or diabetes. 
We have discussed the role of exercise and oxidative stress in section 4. The levels of NO, nNOS, 
and oxidative stress within the RVLM system are important determinants of hypertension, and 
exercise training can restore the high blood pressure to normal blood pressure status by reversing 
the levels of nNOS expression [197]. In humans, nNOS dysfunction may lead to an impairment of 
vascular homeostasis in essential hypertension and contributes to stress-induced cardiovascular 
events [101,198]. Overall, we recognize that nNOS is an important cardiac protector in the 
diseased heart and plays a major role in arteriosclerosis, the most important cause of hypertension, 
coronary artery disease and myocardial infarction [192]. In summary, we have discussed the 
intricate relationship between hypertension and nNOS, particularly about the new findings of 
nNOS and H2O2 interactions for the development of arteriosclerosis, the most important cause of 
human cardiovascular diseases. Nevertheless, the achievement of maintaining a normal blood 
pressure through diet and exercise is possible by every human being, and most importantly, a stable 
normal blood pressure within the physiological range significantly reduces the risks of death as a 
result of heart disease and stroke, the development of other debilitating conditions such as kidney 
failure, and the cost associated with advanced medical care [199,200]. 
 
5. Cerebrovascular Accident or Stroke and Neuronal Nitric Oxide Synthase 
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In the USA, on average, 1 person suffers stroke in every 45 seconds and it continues to escalate 
due to an increasing population of elderly Americans, obesity, an increase in diabetic population, 
sedentary living, and lack of physical activity among the general public. Stroke has been identified 
as the 3rd killer disease in the USA. In 1978, the World Health Organization (WHO) defined stroke 
as a "neurological deficit of cerebrovascular cause that persists beyond 24 hours or is interrupted 
by death within 24 hours." On the other hand, stroke is referred to as a medical situation where 
there is a reduction or even cessation of blood flow to the brain or a part of the brain that results in 
ischemia leading to neuronal cell death, necrosis or infarction [201]. Stroke is also termed 
“cerebrovascular accident” because of its classification into two major categories: “ischemic” and 
“hemorrhagic”. Ischemic strokes are caused by disruption of blood supply to the brain due to 
thrombosis or embolism, while hemorrhagic strokes occur due to rupture of a blood vessel, rupture 
of an aneurysm, or presence of an abnormal blood vessel. Although the major risk factor for an 
occurrence of stroke is high blood pressure or hypertension, other risk factors such as sedentary 
lifestyle, cigarette smoking, obesity, high blood cholesterol/triglycerides, diabetes mellitus, 
previous history of transient ischemic attacks, and atrial/ventricular fibrillation are also implicated 
as etiologies of strokes [201,202]. Because of the fact that cerebrovascular accidents cause a 
tremendous impact on the morbidity and mortality of human beings, a lot of money, time, and 
research have been invested not only for further understanding the pathogenesis and 
pathophysiology of stroke but also for developing new strategies aimed at prevention of and 
treatment and rehabilitation of patients with cerebrovascular accidents.  
Cerebrovascular accidents or brain ischemia initiate a cascade of events: loss of ATP and 
subsequent cellular dysfunction; Na+ and Ca2+ influx causing massive Ca2+-induced release of 
neurotransmitters such as glutamate which results in excitotoxicity and neuronal death mediated 
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via α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and NMDA receptors; 
overproduction of uric acid and lactic acid; cell swelling; and finally apoptosis [189,190,203]. 
Ischemia also activates inflammatory cytokines, causes overexpression of inflammation-related 
genes, attracts leukocytes into the brain tissue, and promotes cellular adhesion [11,14]. Most 
importantly, neuronal death following ischemia is attributed to the progressive generation of free 
radicals and other ROS. Free radicals also directly initiate elements of the programmed cell death 
cascade by means of redox signaling that damages DNA, proteins and lipids, and compromises the 
integrity of the blood brain barrier [204-206]. One such free radical is NO, which is generated 
from neurons, nerve terminals, and/or the endothelium of blood vessels supplying the brain [207-
214]. The production of NO following stroke is dependent on the activation of all 3 isoforms of 
the NOSs enzyme: nNOS, iNOS and eNOS [11,48]. The amount of NO generated by each of these 
isoforms depends on the elapsed time after a stroke and the expression of each NOSs protein; these 
factors also determine whether NO is responsible for protecting or destroying neurons within the 
umbra or penumbra regions [207-214]. The following paragraphs will primarily focus on past and 
recent discoveries about nNOS and its role in the pathogenesis and management of stroke. 
In recent years, the management and therapy for ischemic cerebrovascular accidents in humans 
have progressed rapidly. The latest protocol of clinical management of an acute episode of stroke 
in humans has shown the continued development of conceptual ideas and techniques such as 
mechanical thrombectomy, stenting, and pharmacological interventions with promising results. A 
recent review with in-depth perspective on the advancement in therapy for ischemic 
cerebrovascular diseases in humans has shown that indeed, both timely-performed 
pharmacological and surgical interventions can decrease morbidity and mortality following an 
ischemic stroke attack [215]. While the role and actions of NO and nNOS on stroke in humans are 
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currently being elucidated, its involvement has been already established in the pathogenesis of 
ischemic brain damage in experimental animals. The literature suggests that NO has both 
neuroprotective and neurotoxic effects during the different stages of cerebral ischemia. Which 
effect occurs first or second depends on the time elapsed since the onset of ischemic injury; the 
expression of specific NOSs isoforms; cellular sources of NO from the umbra, penumbra, or other 
regions of the brain; spillover of NO and its metabolites (nitrites and nitrates) into the plasma and 
cerebrospinal fluid; and the amount of NO ultimately generated by each specific NOSs protein 
[171,216,217]. For example, one beneficial effect of NO is the inhibition of glutamate-induced 
Ca2+ influx into neurons, suggesting that NO directly decreases the excitatory glutamatergic 
neurotransmission [218-220]. Furthermore, at the early stages of cerebral ischemia, a surge in NO 
release generated by eNOS seems to protect the neurons from death by inducing vasodilatation 
and inhibiting microvascular aggregation, but in the later stages of stroke, the overproduction of 
NO by nNOS or iNOS contributes to apoptosis and subsequent neuronal death [170,212,216]. 
However, nNOS can have beneficial effects on brain infarct size after stroke [7,48,218]. Exactly 
how much NO is produced by each NOS isoform after cerebral ischemia is unknown, but under 
inflammatory conditions in the brain, the iNOS isoenzyme can generate thousand times more NO 
than the nNOS protein [11]. 
A search of the literature (Last performed on December 20, 2019) reveals very few studies that 
investigate the relationship of nNOS with ischemic stroke in humans in terms of both pathogenesis 
and clinical management. Our search includes the International Standard Randomized Controlled 
Trial Number (ISRCTN), Stroke Trials Registry, Cochrane Stroke Group Trials Register, Embase, 
ISI Science Citation Indexes, Clinical Trials registry, International Clinical Trials Registry 
Platform (ICTRP) and MEDLINE. One of the selection criteria has been randomized controlled 
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trials comparing nNOS versus placebo or open control in people within one week of onset 
following a confirmed stroke. Upon examining all search, there is currently insufficient evidence 
to recommend the use of the nNOS protein agonists or antagonist in an acute episode of stroke in 
humans, however, a NO donor, glyceryl trinitrate (GTN) has been assessed in patients with acute 
stroke, where the drug reduces blood pressure and increases HR, but does not alter the clinical 
outcome of stroke [221]. Our conclusion has been corroborated by a recent review [221]. We do 
not have any knowledge if there are other ongoing case-controlled studies or clinical trials. 
Nevertheless, there are some noteworthy discoveries on the role of nNOS in human disease 
processes. For example, a case control study performed on the Han Chinese population of North 
China has shown that there is indeed several gene polymorphism of the nNOS protein that is related 
to ischemic stroke [222]. Another study assessed whether variants in the nNOS gene were 
associated with atherosclerosis and stroke susceptibility in the human population, in which it has 
been shown that the T allele of rs2293050 and A allele of rs2139733 in the nNOS gene may 
contribute to the increased susceptibility of large-artery atherosclerosis-induced ischemic stroke 
[223]. However, in humans, the relationship between hypertension and stroke has been well-
established. It appears that nNOS plays a significant role in the pathogenesis of hypertension (see 
“Hypertension and nNOS” section). For example, in humans, nNOS-derived NO has been shown 
to play a crucial role in the physiological regulation of basal systemic vascular resistance and 
arterial pressure [189]. Recanalization of atherosclerotic cerebral blood vessel(s) and 
neuroprotection are the main targeted foci for the specific treatment of acute ischemic stroke in 
humans. A novel drug, edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), is a potent free radical 
scavenger that has been used clinically for a long time in order to lessen the neuronal damage 
following ischemic stroke [224]. Edaravone has a profound effect on NOSs, mediated via 
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increasing the eNOS isoenzyme (neuroprotective NOS after ischemic stroke) and decreasing the 
nNOS and iNOS proteins or the “so-called neurotoxic NOS” [224]. Furthermore, it has been shown 
that a thrombolytic drug along with edaravone have the greatest potential to reduce brain edema, 
decrease the number of stroke-related deaths, and enhance the recovery from neurological deficits 
in human stroke patients. Nevertheless, more studies are necessary in order to fully establish and 
justify the use of nNOS agonists or antagonists for the prevention and/or management of stroke 
using human subjects. 
The effects of NO, and particularly that of nNOS, have been studied most extensively by the 
administration of NO donors, NO precursors, specific NOSs isoform blockers, and glutamate 
receptor antagonists in both human stroke patients and animal models of cerebral ischemia 
[22,225]. One study from our laboratory using the standard rat model of stroke shows that a 
transient left-sided middle cerebral artery occlusion (MCAO)-induced focal ischemia followed by 
24 hours of reperfusion significantly attenuates nNOS expression within the left (ipsilateral) 
RVLM relative to the contralateral RVLM (Figure 6) [158]. Simultaneously, nNOS protein 
expression within the ipsilateral CVLM following a left-sided MCAO is significantly augmented 
compared to the contralateral CVLM (Figure 6; Ally et al., 2005). These results suggest that one-
sided temporary ischemic stroke affects ipsilateral nNOS protein expression within the VLM, 
which in turn, may result in the attenuation of cardiovascular responses during static exercise 
[158,162]. Similar results were obtained with the expression of eNOS protein within the medulla, 
whereas opposite changes in the expression of the iNOS isoform within the RVLM and CVLM 
after stroke are observed in our experiments with rats [12,157]. Moreover, the literature has 
extensive studies regarding the role of nNOS protein during ischemic stroke in animal models and 




Figure 6: A picture of a gel with Western blots of the 155 KDa recombinant nNOS band and nNOS 
proteins as derived from each quadrant of the right and left rostral (RVLM) and caudal ventrolateral 
medulla (CVLM) homogenates of intact or Sham and middle cerebral artery occluded (MCAO) rats. Equal 
amounts of proteins (20 μg) were loaded in each lane in the same gel.  Recombinant nNOS DNA (5μg: 
Sigma Chemicals, USA) was loaded as control. 
 
In a recent study using mice, it has been shown that the dissociation of nNOS from the 
postsynaptic density protein 95 (PSD95) is associated with functional recovery after cerebral 
ischemia that is mediated via decreasing the excessive tonic release of GABA from reactive 
astrocytes [226]. Note that stroke induces massive releases of both GABA and glutamate from 
neurons (see above). In the same line, a small aminosulphonate compound called tramiprosate, 
that is present in various species of red marine algae, provides a dose-dependent neuroprotection 
both in vitro and in vivo models of ischemic stroke, and that its neuroprotective effect may partially 
be mediated via disruption of the PSD95 and nNOS interaction, in addition to translocation of the 
nNOS isoenzyme [148]. Furthermore, atorvastatin, a lipid lowering statin medication that is also 
involved in phosphorylation of nNOS, has been shown to provide the neuroprotection following 
ischemic brain injury that is mediated through suppression of the JNK3 signaling pathway, which 
may emerge as a new concept for the management of stroke in the future [227]. In addition, a study 
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using the rat model of MCAO-induced stroke demonstrates a destructive 
nNOS/peroxynitrite/AMPK cascade following stroke, and that treatment with S-nitrosoglutathione 
can attenuate the injurious cycle that in turn, may provide neuroprotection and ameliorate 
neurological functional activity [228]. Indeed, the nNOS protein has been shown to play a crucial 
role in the disruption of blood brain barrier following a transient focal cerebral ischemia by MCAO 
[69]. Overall, the above studies show potential rationales of using nNOS-based therapy in the 
management of stroke or cerebral ischemia-related pathologies in the future. 
The importance of exercise and NO-based therapeutic strategies for preventing and treating 
stroke cannot be underestimated. According to the American Heart Association, aggressive 
physical rehabilitation of stroke patients with exercise facilitates recovery of motor functions and 
also significantly increases peak left ventricular ejection fraction and high-density lipoprotein 
cholesterol, and decreases resting HR and total serum cholesterol [229,230]. The beneficial effects 
of exercise intervention, including isometric or static exercise, include improvements in aerobic 
capacity, functional ability, lipid profile, physical activity, neuroprotection, and a speedy recovery 
after stroke. It is noteworthy to state that exercise is also recommended to prevent the incidence of 
stroke [229,230]. In the event of a stroke, both exercise and/or pharmacological/surgical 
interventions are integral regimens of a treatment protocol. Adjuvant drugs are used to reverse or 
block the molecular, cellular and biochemical events in the brain occurring as a result of the stroke 
in order to treat stroke-related signs and symptoms and to reduce brain infarct size. Overall, it has 
been demonstrated that regular physical exercise, endurance exercise, and even regular swimming 
improve total antioxidant capacity, prevent neurodegeneration due to redox, and attenuate 
oxidative damage with increases in antioxidant defenses [231-233].  
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Exercise is also beneficial and likely exerts its effect, at least in part, through the NO and NOSs 
system [234-236]. For example, it has been shown that regular exercise training recovers high fat 
diet-induced nNOS expression within the hippocampus and cerebral cortex of mice [237]. 
Furthermore, enhanced NO-signaling pathways mediated via the induction of the nNOS protein 
within the PVN and the dorsomedial hypothalamus (DMH) play a critical role in improving 
exercise capacity after central administration of an NO precursor, L-Arginine [238]. Regular 
swimming training by rats can modulate NO-glutamate interaction within the RVLM [235]. 
Aerobic exercise improves the functioning of the brain mediated via modulation of the nNOS 
proteins within the brain [239]. In addition, regular exercise restores oxidative stress and NOSs, 
including nNOS, within the RVLM of hypertensive rats and that exercise induces production of 
NO molecules [197,236]. Finally, it has been demonstrated that vigorous exercise training protocol 
indeed improves the reactivity of cerebral arterioles that follows after an acute episode of transient 
focal ischemia that in turn, reduces brain injury or neuronal damage [240]. 
A decrease in blood pressure following i.c.v. administration of an NO donor is associated with 
the overexpression of nNOS mRNA within the RVLM. Following stroke, the surge in glutamate 
release appears to be toxic, the massive release of GABA being protective, and the amount of NO 
molecules generated can have either beneficial or deleterious effects on neurons and/or the brain 
as a whole. Administration of NO donors can be useful within the first few hours after an attack 
of ischemic stroke in order to induce vasodilation and an increase in blood flow to the affected 
areas [229,241]. Nitric oxide donors are currently used to treat platelet aggregation and embolus 
formation in blood vessels, both predisposing factors for stroke, and that human-derived nNOS 
inhibitors are in the early clinical stages for treating headache and migraine [242]. Thus, studies 
are focusing on nNOS using both vertebrate animals and humans [7,9,217]. Nonetheless, clinical 
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experience with NO for the treatment of stroke in humans is limited. Many nNOS inhibitors also 
possess antioxidant properties and can be neuroprotective. Activation of the iNOS protein 
generates a massive amount of NO that diffuses to other brain regions via the cerebrospinal fluid 
and therefore, selective iNOS inhibitors could be valuable therapeutic tools for treating human 
stroke. Therapeutic strategies using NO donors, NO precursors, or selective NOSs inhibitors are 
rapidly emerging based on their effects on transcription factors at the mRNA level and subsequent 
expression of the respective protein using a variety of in vitro and in vivo experiments [7,9,217]. 
It is interesting to speculate whether administration of pharmacological drugs before or after stroke 
can maintain or recover the normal expression of any or all of the NOSs isoforms and 
neurochemistry within the VLM, and thus improve cardiovascular functions at rest and also during 
exercise. In conclusion, this section summarizes the crucial role that the nNOS isoform plays in 
the pathophysiology and management or treatment strategies of cerebrovascular accidents, and 
provides further insight into the potential use of the nNOS protein modulators in clinical practice 
in the future. 
 
6. Nociception and Neuronal Nitric Oxide Synthase 
The term "nociception" was first introduced by Dr. Charles Scott Sherrington while 
describing physiological processes particularly of the sensory nervous activity due to a subjective 
experience of pain [243-245]. The stimulus or stimuli that may cause pain can be either due to an 
intense chemical contact such as eating too much chili powder, or as a result of mechanical 
manipulation like a cut on the skin or a crushing accident on the leg, or can be due to a thermal 
effect such as too much heat (burn) or exposure to extreme cold [246]. Any of the above-mentioned 
stimuli activates sensory nerve cells called “nociceptors” and the responding signal travels along 
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a series of nerve fibers to the spinal cord and finally reaches different areas of the brain. The 
medulla oblongata, the hypothalamus, the PAG, and/or the thalamus within the brain integrate the 
nociceptive signal(s) in order to evoke a variety of physiological, behavioral and/or defensive 
responses: responses arising from the subjective experience of pain. The factors and the type of 
stimulus such as proprioception, thermoception, chemoception and nociception are all integrally 
connected. The variety of bodily responses caused by pain, for example, how nociception results 
in autonomic responses before or without reaching unconsciousness e.g., pallor, diaphoresis, 
tachycardia, hypertension, dizziness, nausea and fainting is well established. One of the responses 
that are a result of pain is alteration of the cardiovascular function such as blood pressure or HR. 
The following paragraphs will review the literature and scientific publications that relate to the 
interaction between the CVS and nociception and how that involvement is associated with NO, 
particularly with the nNOS isoenzyme. 
The various cardiovascular responses due to pain are alterations in blood pressure, HR, 
sympathetic nerve activity, myocardial contractility, stroke volume, ejection fraction, and changes 
in EKG properties and they depend on the type of pain, intensity of pain, involvement of specific 
nociceptor or pathways, and the type(s) of neurotransmitter/receptor(s) involved such as serotonin, 
opioid, or NMDA/AMPA glutamate receptors. For example, pain generally influences the CVS 
and that the afferent signals from peripheral pain receptors terminate within different regions in 
the CNS including the cardiovascular regulatory centers, where the impulses are processed and 
integrated in order to evoke the above-mentioned reflexes and responses [247-251]. Our laboratory 
has previously shown that indeed mechanically-induced and heat-mediated thermal nociception 
increase MAP and HR in an intensity-dependent manner, however, a cold-evoked nociceptive 
stimulus causes depressor and bradycardic responses [252-255]. Several reviews on pain and 
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cardiovascular activities including recent publications about nociception corroborate our findings.  
For example, in proportion to the intensity and duration of a pain stimulus, multiple ascending 
spinal reflexes/impulses activate the SANS in order to increase peripheral vasoconstriction, MAP, 
HR, and stroke volume in addition to activating the neuroendocrine system, particularly the 
hypothalamic-pituitary-adrenal system [256,257]. By monitoring EKG changes, blood pressure, 
respiratory rate and postganglionic sympathetic discharge activity (muscle sympathetic nerve 
activity or MSNA) in human subjects, scientists reveal a hypothetical possibility that in 
Fibromyalgia patients, the use of adrenergic antagonists may reduce chronic pain intensity by 
attenuating the underlying overactive and excessive sympathetic activity [258]. Moreover, a study 
shows that the African-American populations experience a greater intensity of muscle pain than 
non-hispanic white population during static or isometric handgrip exercise, however, both group 
exhibit similar increases in MAP and HR [256]. Finally, high blood pressure is one of the most 
common co-existing manifestations observed in patients suffering from chronic pain, including 
the fact that there is a rise in resting MAP due to acute postoperative pain in dental patients after 
an endodontic surgery [259,260]. In summary, it is well-established that the cardiovascular and 
nociceptive systems are interrelated and that their interactions lead to several manifestations in 
bodily homeostasis and defensive/withdrawal reactions. 
The multiplicity of mechanisms, vast arrays of neurotransmitter involvement, regions of 
brain participation, specific receptor interactions, management and treatment, and above all, the 
relationship between pain and the CVS have been widely studied and are still regarded as active 
ongoing investigation. A recent chapter in a book describes the medications along with their 
toxicological side-effects that are used in the treatment of pain in patients with peripheral 
neuropathy, including their side-effects on cardiovascular function. Our laboratory also 
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investigated the relationship between cardiovascular functions and different receptor-
neurotransmitter interactions during several modes of nociceptive stimulus. We have shown that 
AMPA-receptor blockade within the RVLM attenuates the increases in MAP and HR elicited 
during mechanically-induced nociception and associated with a reduction in extracellular levels of 
glutamate, while antagonism of AMPA receptors in the RVLM do not play a role in mediating 
cardiovascular responses during thermally-evoked nociception [255]. In addition, we show that 
NMDA receptors within the RVLM play a critical role in altering the enhanced cardiovascular 
responses during mechanically-induced but not during thermally-evoked nociception by 
modulating 5-Hydroxytryptamine (5HT), epinephrine (EPI), and dopamine (DA) concentrations 
within the RVLM [253,254].  Thus, it can be emphasized that indeed nociception involves a wide 
variety of mechanistic and conceptual information that are yet to be fully delineated in order to 
understand the overall science of “pain”. 
Nitric oxide, the molecule of the year 1992 and the Nobel Prize in 1998, and all three NOSs 
isoenzymes have been implicated in nociception and cardiovascular responses as a result of pain. 
For example, BH4 is a crucial cofactor for the production of catecholamine, serotonin and NO, 
thereby acting as an intrinsic regulator of pain-induced sensitivity. Numerous studies have shown 
that GTP cyclohydrolase (GCH1), which is a rate-limiting enzyme for the synthesis and production 
of BH4, is an important modulator of peripheral neuropathy- and inflammation-induced pain 
[257,261]. However, high concentrations of NO appear to be cytotoxic in situations such as 
peripheral neuropathy, neurotoxicity and pathological pain [262]. Thus, NO is regarded as an 
important neurotransmitter involved in the nociceptive processes/pathways. Various reviews and 
studies in both humans and experimental animals indicate that NO and all three NOSs modulate 
spinal and sensory neuronal excitability via multi-staged mechanisms that underlie NO’s specific 
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and distinctive roles in pain. Both eNOS and iNOS proteins are involved in neuropathic pain [257] 
and the following paragraphs will summarize the recent findings about the interactions between 
nociception and cardiovascular functions in relation to nNOS.   
As mentioned earlier, nNOS protein is constitutively expressed in specific neurons of the 
brain, spinal cord, sympathetic ganglia, adrenal cortex/medulla, peripheral nitroxidergic nerves, 
epithelial cells and vascular smooth muscles; the nNOS activity on vascular smooth muscle cells 
being regulated by Ca2+ and CaM mechanism. The overall functions of nNOS are both long-term 
and short-term regulation of synaptic transmission within the CNS, control and regulation of 
arterial blood pressure, and smooth muscle relaxation leading to vasodilation [257]. Particularly, 
nNOS has been shown to play a very important dynamic role in neuronal death due to an episode 
of cerebrovascular accident such as stroke [48]. However, the role of nNOS on nociception has 
been the focus of numerous investigations involving both humans and animals. A recent study 
demonstrates that stimulation of spinal sigma-1 receptors (Sig-1Rs) elicits pain hypersensitivity 
and is mediated via activating the nNOS enzyme, that leads to an increase in NADP oxidase 2 
(NOX2) activity which in turn, may result in a ROS-induced increase in protein kinase C (PKC)-
dependent phosphorylation of NMDAR-GluN1 subunit (pGluN1) at the Ser896 site of the spinal 
cord [263]. In addition, an increase in phosphorylated nNOS isoenzyme has been shown to be 
associated with neuropathic pain in rats [264]. Overproduction of NO by the nNOS isoform is one 
of the fundamental cause that underlie many neurodegenerative disorders and neuropathic pain 
and mediates the upregulation of the expression of the nNOS isoenzyme [58]. Neuronal NOS may 
also induce neuronal death via peroxynitrite formation, thereby enhancing the phosphorylation of 
NMDAR and resulting in central sensitization, which in turn, via the production of NO maintains 
persistent or chronic pain [57].  In addition, the role of nNOS in diabetic neuropathic pain has been 
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studied. In the early stages of diabetes mellitus Type 1 disease, the expression of nNOS within the 
nitroxidergic neurons is reduced as a result of less production of NO and associated with a defect 
in the axonal transport of nNOS protein, however, during the late phases of the disease, neurons 
appear to drastically reduce their nNOS enzyme resulting in irreversible apoptotic degenerative 
changes [265]. It has been proposed that small molecule inhibitors of the scaffolding protein 
postsynaptic density 95 kDA (PSD95)-nNOS protein-protein interactions as novel analgesics that 
act by attenuating pathological pain without producing any unwanted side effects such as motor 
ataxia [266]. In fact, the discovery of a potent, orally bioavailable and highly selective human 
nNOS inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide has led to the 
development of pre-clinical trials for the treatment of migraine headache [267]. Other novel 
compounds that selectively block nNOS-induced NO production has been discovered that are 
aimed at alleviating neuropathy-associated pain without any cardiovascular side-effects [267,268].  
Our laboratory has studied the role of NO and all three NOSs enzymes in different regions 
of the brain that modulate cardiovascular responses and neurotransmission (glutamatergic and 
GABAergic) during mechanically-induced, heat-induced, and cold-generated nociceptive stimuli. 
Our first research on nociception began on experiments with modulation of cardiovascular 
functions via glutamatergic neurotransmission following AMPA-receptor blockade within the 
RVLM during different modalities of peripheral pain in the year 2001 using rats. Our experimental 
results show that the AMPA-receptor antagonism within the RVLM attenuates the increases in 
MAP and HR during mechanical stimulation that is associated with a reduction in extracellular 
levels of glutamate within the RVLM, however, AMPA receptors blockade within the RVLM do 
not modulate cardiovascular responses during thermal nociception. Thereafter, we have 
investigated what role NO plays within the VLM on modulating cardiovascular responses and 
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neurotransmission during mechanical and thermal nociception. Nitric oxide affects cardiovascular 
responses by altering glutamate concentrations within the RVLM during thermal but not 
mechanical nociception, suggesting that differential integrative mechanisms regulate the 
processing of sensory ascending and descending impulses arising from different peripheral 
nociception [159]. We have also shown that NMDA receptors within the RVLM modulates 
increases in MAP and HR by changes in the concentrations of 5HT and DA within the RVLM 
during mechanically-induced but not during thermal nociception [253,254]. In addition, NO within 
the dorsal dPAG attenuates cardiovascular responses and changes in the concentrations of 
glutamate during both mechanical and thermal nociceptive stimulation [163]. Bilateral 
microdialysis of a selective nNOS antagonist, 1-(2-trifluoromethyl phenyl)-imidazole or TRIM 
into the dPAG has no effect on MAP, HR, glutamate and GABA concentrations as a result of 
mechanical nociception, however, administration of TRIM into the dPAG significantly enhances 
the cardiovascular responses and glutamate increases but attenuates concentrations of GABA 
during a heat-induced thermal nociception, suggesting that nNOS within the dPAG plays a 
differential role in modulating cardiovascular responses and glutamatergic/GABAergic 
neurotransmission during different modes of nociception [253]. We have also demonstrated the 
effects of iNOS and eNOS blockade within the dPAG on cardiovascular responses during 
mechanically-induced, heat-elicited, and cold-evoked peripheral nociception [119,252]. 
In summary, uncoupling and over-expression or down-regulation of NOSs isoforms play a 
crucial role in neuropathic pain mediated via numerous processes or mechanisms, i.e., mediating 
neuronal excitotoxicity by activating NMDA receptors and numerous transcription pathways 
(MAPK, JNK, and ERK pathways) that may lead to the death of neurons. All three NOSs appear 
to generate high concentration of NO, leading to neuronal toxicity by the production of 
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peroxynitrite, a neurotoxic compound. Literature shows that both nNOS and iNOS contribute 
considerably to the generation of neuropathic pain, however, not much has been investigated about 
the role of eNOS in neuropathic pain. Nevertheless, pharmacological interventions with NOS 
isoform agonist and antagonists and their downstream mediators/regulators/signal transduction 
processes may restart the development of potential therapeutic agents for the treatment of 
neuropathic and other pain with desirable or mitigated cardiovascular effects. 
 
7. Highlights and Conclusion 
In this review, we elaborate past and recent discoveries regarding nNOS and its redox 
properties along with its diverse role on the CVS in both physiological and pathological states such 
as stroke and hypertension. In addition, we have narrated the involvement of the nNOS protein in 
neurotransmission, neuroprotection and neurotoxicity, smooth and skeletal muscle contraction, 
sexual function/dysfunction, body fluid homeostasis, and atherosclerosis, among others. 
Consistent with the involvement of nNOS in such various aspects of human biology, we now know 
that nNOS mRNA and the protein are expressed in numerous tissues. We have shown the genetic 
organization of the nNOS mRNA and bidomain structure of the nNOS protein isoform. It appears 
that both its gene structure and expressional regulation are exceedingly complex. The location of 
nNOS gene on chromosome 12 holds tremendous clinical significance because the same gene 
encodes NO production and regulation of vascular hypertension. This paradoxical concept plays 
an important role in the understanding of pathological mechanisms of many cardiovascular 
diseases. 
We describe that the nNOS gene produces multiple mRNA transcripts via a variety of 
intriguing mechanisms: alternate promoter usage, alternative splicing, cassette 
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insertions/deletions, varied sites for 3'-UTR cleavage and polyadenylation. There are now four 
different variants of the nNOS protein, i.e., nNOSαa, nNOSαb, nNOSβ, and nNOSγ. Because of 
the fact that nNOS mediates H2O2-induced arteriosclerosis, it is pertinent to find out which variant 
is responsible for such an important vasculopathy. If we can determine that, then we can develop 
and discover specific antagonists of such nNOS variant(s) that in turn, may lead to potential 
pharmacotherapies of atherosclerosis and atherosclerosis-induced myocardial infarction, stroke, 
and/or thrombosis. In addition, we describe the specific binding sites and the various receptors 
associated with nNOS. Taken together, the vast array of properties and structure-related actions of 
nNOS make the protein as one of the most complex human genes and thus, understanding the 
intricate genetic regulation of nNOS has been a major focus in continuing further research on 
nNOS along with its medical, biological, and clinical implications. 
While describing the various actions of the nNOS protein on the CVS, we can establish 
that nNOS-induced NO release is a very important determinant of maintaining basal vascular tone; 
preventing platelet activation and aggregation; limiting the adhesion of white blood cells to the 
endothelial wall of arteries; regulating myocyte contractility; and mediating, modulating and 
integrating the regulation of the overall cardiovascular functions. Neuronal NOS delays the 
transition to heart failure in response to pressure overload, protects the myocardium from 
functional deterioration after an episode of myocardial infarction, and decreases mortality after an 
incident of myocardium infarction or heart attack. In addition, the nNOS protein plays a key role 
in the pathogenesis of common cardiovascular diseases that includes hypotensive shock, essential 
hypertension, atherosclerosis, ischemic cardiovascular disease, and heart failure.  
The role of nNOS in cardiomyocyte functions and their increasing contractility mediated 
via the ryanodine receptors and Ca2+ release from the SR has been described, however, the role of 
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nNOS in normal cardiac myocyte function has been shown to be controversial. Neuronal NOS acts 
as a relay between ryanodine receptors and Ca2+ by inhibiting SR import pump & SERCA, 
increasing Ca2+ levels in the cytoplasm, and thereby resulting in positive ionotropic and 
dromotropic effects. On the other hand, inhibition of nNOS activity either by gene disruption or 
by pharmacological antagonism can potentiate myocardial contractility at physiological 
temperatures. Such nNOS blockade can also inhibit SERCA over a wide range of HR values and 
simultaneously augment phospholamban levels in order to cause negative ionotropic and 
dromotropic effects. Moreover, nNOS-induced production of NO inhibits the L-type Ca2+ currents 
via the NO-cGMP pathway as a result of attenuating guanylate cyclase-derived increases in peak 
Ca2+ current. Most probably, in non-damaged myocardium nNOS activity is regulated by beat-to-
beat variations in intracellular Ca2+ levels. In pathological conditions of the heart, nNOS can 
decrease myocardial contractility via inhibition of the L-type Ca2+ current amplitude and the 
intrinsic Ca2+ transients. The mitochondria and xanthine oxidoreductase enzyme inside a cardiac 
myocyte are potential targets for nNOS in cardiac disease models. Neuronal NOS, Ca2+-CaMPKII 
and NOX2 are important mediators in mechanical and chemical transduction processes that occur 
during cardiac contraction, and can be targeted by new therapeutic approaches for treating stress-
induced Ca2+ dysregulation, cardiac arrhythmias, and cardiomyopathy. The role of oxidants, ROS 
and nNOS on Ca2+ and Na+ movements in healthy and diseased cardiac myocytes in the case of 
cardiac ischemia-reperfusion injury has been elaborated in our review. Ischemic postconditioning 
can provide protection of the heart following an ischemia-reperfusion injury to the heart mediated 
via nNOS located within the SR and mitochondria. 
Atrial fibrillation is a growing public health burden and its effective treatment always 
remains a challenge. Atrial fibrillation leads to electrical remodeling of the atria, which in turn 
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promotes the continued maintenance of atrial fibrillation and resistance to treatment. Although 
treatment of congestive heart failure and associated atrial fibrillation by ACE inhibitors or ARBs 
are geared towards cardiac remodeling, however, the main cause of atrial fibrillation still remains 
poorly understood. In this review, we describe how atrium-specific upregulation of miRNA-32 
can be an electrical phenotype in human atrial fibrillation and the key mechanism being the loss 
of atrial dystrophin and nNOS proteins. Thus, miRNA-31 may represent a potential therapeutic 
target in cases of atrial fibrillation. Overall, we state that nNOS is a predominant isoform of the 
NOSs that controls intracellular Ca2+ homeostasis, myocardial contraction, cardiac relaxation, and 
the signaling pathways, including the balancing of nitroso-redox. Furthermore, we describe that 
nNOS is induced by the interplay between AngII type 1 receptor and Ang II type 2 receptor and 
mediated by NADPH oxidase and ROS-dependent nNOS activity in cardiac myocytes. Neuronal 
NOS can protect the heart from the pathological changes during hypertensive state, and thus can 
be a basis for future investigation of new drugs targeted towards hypertension-induced diseased 
myocardium.  
While describing the actions of nNOS on vascular tone, we have mentioned that nNOS is 
also present on the endothelial cells and that it contributes to the modulation of vascular perfusion. 
In case of a sudden rise in blood pressure, homeostatic mechanisms kick in and trigger the release 
of NO that will increase the diameter of the vascular lumen and decrease the total peripheral 
resistance, an important parameter used in the calculation of blood pressure. Both eNOS and nNOS 
have their separate distinctive roles in the physiological regulation of human microvascular tone 
in vivo and should be further studied for understanding the pathogenesis of vascular remodeling 
and vasculopathy in cases of arteriosclerosis and venous thrombosis. We also discuss the role of 
nNOS on the transcription regulatory systems during angiogenesis, including its role on the 
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dynamics of renal blood flow during vasodilation or vasoconstriction. The nNOS isoform is a 
critical regulator of renal hemodynamics in the newborn and hence the nNOS-derived NO-cyclic 
GMP pathway has the potential to be an important target for the treatment of renal circulatory 
dysfunction such as chronic kidney failure and uremia. Chronic interference of the nNOS protein 
dimerization that is responsible for the production of NO within the PVN of the hypothalamus 
potentiates the rises in blood pressure via modulating the sympathoexcitation associated with 
renovascular hypertension. These effects of nNOS on vascular system can lead to the further 
development of strategies in the treatment of vascular disorders including ischemic situations. 
Lastly, but not the least, nNOS has its own distinctive role in the physiological regulation of human 
coronary vascular tone in vivo. Overall, we have summarized the role of the nNOS protein on the 
vasculature during both physiological state and pathological situations.  
We also discuss the role of nNOS in SANS and PANS including its involvement in several 
brain regions associated with cardiovascular regulation and functions. We mention the interaction 
of nNOS with glutamatergic and GABAergic neurotransmission and cardiovascular regulation 
within the VLM, the NTS, and the hypothalamus. We have discussed that nNOS within the RVLM 
is sympathoinhibitory in pathological conditions like congestive cardiac failure, chronic renal 
failure, hypertension, and diabetes, and that there is evidence that the nNOS protein has significant 
interactions with both glutamate and GABA in the regulation of the overall CVS. Redox-sensitive 
inhibition of nNOS-mediated nNOS uncoupling is associated with overproduction of ROS within 
the RVLM, and may result in the sympathetic overactivity-induced hypertension that is observed 
in Metabolic Syndrome. 
We also elaborate that nNOS activity within the RVLM and CVLM plays opposite roles in 
modifying cardiovascular responses during peripheral stimulus mediated through glutamate and 
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GABA neurotransmission. Blockade of nNOS within the RVLM increases glutamate release and 
decreases GABA levels, and the result is enhancement of pressor and tachycardic responses as 
observed during exercise, whereas nNOS antagonism within the CVLM causes attenuation of 
blood pressure and HR increases in response to exercise by a reduction in neuronal glutamate 
release and increase in GABA levels within the CVLM. In addition, we discuss that NO-nNOS 
system plays an important role in baroreflex mechanism in both physiological and 
pathophysiological states. Selective blockade of nNOS reduces vagally-mediated decreases in HR. 
Moreover, systemic administration of nNOS inhibitors affects baroreflex activity via modulating 
peripheral autonomic transmission, postsynaptic responsiveness of target tissues to autonomic 
stimuli, and the ANS circuitry within the CNS. Finally, any insult during dimerization process of 
the nNOS protein within the PVN of the hypothalamus may cause renovascular hypertension. The 
hypothalamus controls human circadian rhythms and diurnal variations in blood pressure and is 
critical for circadian blood pressure dysfunction and essential hypertension. 
We also narrate the role of nNOS in cerebrovascular accident or stroke. The nNOS-induced 
neuronal release of NO can be considered as a free radical. The production of NO following stroke 
is dependent on the changes in the abundance of each isoform of NOSs and that nNOS can be 
either neuroprotective or neurotoxic during the different stages of cerebral ischemia. The 
pathological changes happening after a stroke depend on the time elapsed after the onset of the 
stroke and the subsequent expression of specific NOSs isoforms; the amount of NO that was 
generated by each specific NOSs protein; the effects of NO on the cells within the umbra, 
penumbra, or other regions of the brain; and on how much NO and its metabolites have entered 
the plasma or the brain ventricles. At the very early stage of cerebral ischemia, a surge in the 
release of NO by the eNOS protein appear to protect neuronal death by inducing vasodilatation 
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and inhibiting microvascular aggregation, but later on, too much of NO produced by either nNOS 
or iNOS may contribute to apoptosis and subsequent neuronal death. Thus, administration of NO 
donors can be useful within the first few hours after an attack of ischemic stroke and selective 
iNOS or perhaps nNOS inhibitors could be valuable therapeutic tools as a part of the treatment 
protocol. 
Because nNOS-derived NO plays a crucial role in the physiological regulation of basal 
systemic vascular resistance, arterial pressure, recanalization of atherosclerotic cerebral blood 
vessel(s), and neuroprotection, it can be used as a part of the treatment regimen for acute ischemic 
stroke in humans. Edaravone, a free radical scavenger, has been used clinically for a long time in 
order to provide neuroprotection following an episode of ischemic stroke. Any thrombolytic drug 
along with edaravone has the greatest potential to be utilized in human stroke patients. Atorvastatin 
may also provide additional neuroprotection following an ischemic brain injury. On the other hand, 
the dissociation of nNOS from the PSD95 is associated with functional recovery after cerebral 
ischemia. Finally, we can state that regular physical exercise like swimming can increase 
antioxidant capacity, prevent neurodegeneration due to redox, and attenuate oxidative damages. 
In this review, we describe the role of nNOS in hypertension and nociception. It is well 
known that hypertension is a prevalent risk factor of fatal cardiovascular complications, such as 
stroke, sudden cardiac death, and heart failure. We discuss past and recent findings about the 
relationship between hypertension and nNOS-induced NO production. Reduced NO 
bioavailability in the endothelium is an important precursor of impaired vasodilation and a 
predisposing factor in the development of hypertension. Neuronal NOS can produce H2O2 and 
superoxide, key mediators in non-neuronal cells signaling, and they promote arteriosclerosis. Thus, 
the role of nNOS in vascular homeostasis and cardiovascular diseases such as hypertension and 
62 
 
atherosclerosis deserve to be explored. Nevertheless, nNOS has been proposed to play important 
roles in suppressing arteriosclerotic vascular lesion and that nNOS protects from atherosclerosis 
[269-272]. We recognize that nNOS is an important cardiac protector in the diseased heart and 
plays a major role in arteriosclerosis, the most important cause of coronary artery disease and heart 
attack.  
Regarding the nociceptive system, cardiovascular and pain mechanisms lead to various 
responses and defensive/withdrawal reactions. Nitric oxide and all three NOSs are involved in 
nociception and cardiovascular functions, and that NO is an important neurotransmitter involved 
in both CVS and nociceptive processes/pathways. Uncoupling, over-expression, or down-
regulation of NOSs isoforms, particularly of nNOS, plays a crucial role in neuropathic pain 
mediated via numerous processes or mechanisms such as neuronal excitotoxicity by activating 
NMDAR or via activating MAPK, JNK, and ERK transcription pathways that may lead to the 
death of neurons. It appears that all three NOSs generate high concentrations of NO leading to 
neuronal toxicity by the production of peroxynitrite, a neurotoxic compound. 
Overall, we have attempted to summarize the numerous roles of the nNOS protein on 
physiological homeostasis involving its structure-activity relationship, gene variants, the CVS and 
nociception, and on some important pathological disease states like vascular ischemia, 
arteriosclerosis, hypertension, congestive cardiac failure, arrhythmias, and stroke. Thus, the 
importance of nNOS cannot be underestimated and we foresee that both basic and clinical research 
with the nNOS protein will continue for decades to come and scientists will someday unravel the 
potential therapeutic value of the nNOS protein, its antagonists, or its variants. 
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